31 S T A N NU A LSYMPOSIUM
OF THE

INTERNATIONAL CANNABINOIDRESEARCH SOCIETY
JERUSALEMISRAELJ U NE 3 0 – J U L Y 5 , 2 0 1 8

PR ELIMI NARY PR OG RAMM E

31 ST A N N U A LSYMPOSIUM OF THE

INTERNATIONAL CANNABINOIDRESEARCH SOCIETY

JERUSALEMJUNE 21 – 24, 2021

Symposium Programming by Cortical Systematics LLC

Copyright © 2021

International Cannabinoid Research Society
Research Triangle Park, NC
USA

PRELIMINARY PROGRAMME – SUBJECT TO MINOR CHANGESAS OUR SYMPOSIUM PROGRAMME IS VIRTUAL THIS YEAR,
ALL TIMES LISTED HEREIN ARE APPROXIMATE.

These abstracts may be cited in the scientific literature as follows:
Author(s), Abstract Title (2021) 31st Annual Symposium on the Cannabinoids,
International Cannabinoid Research Society, Research Triangle Park, NC, USA, Page #.

Funding for this conference was made possible in part by grant R13DA016280 from the
National Institute on Drug Abuse. The views expressed in written conference materials or
publications and by speakers and moderators do not necessarily reflect the official policiesof the Department of Health and Human Services; nor does mention by trade names,
commercial practices, or organizations imply endorsement by the U.S. Government.

2021 Symposium on the Cannabinoids
Conference Coordinators
Melanie Kelly, Ph.D.
Jason B. Schechter, Ph.D.
Yossi Tam, D.M.D., Ph.D.
Sara Whynot
Shlomi Ashkenazi - VERUS
Rami Laor - VERUS

Programme Committee
Irit Akirav, Ph.D.
Steve Alexander, Ph.D.
Heather Bradshaw, Ph.D.
Stevie Britch, Ph.D.
Resat Cinar, Ph.D
Ziva Cooper, Ph.D.
Ben Cravatt, Ph.D.
Elyad Davi dson, M.D.
Vi ncenzo Di Marzo, Ph.D.
Abraham J. Domb, Ph.D.
Javi er Fernández- Rui z, Ph.D.
David Finn, Ph.D.
Jürg Gertsch, Ph.D.
Josee Gui ndon, Ph.D.
Matt Hill, Ph.D.
Cecilia Hillard, Ph.D.
Andrea Hohmann, Ph.D.
Tony Jourdan, Ph.D.
Mel Kelly, Ph.D.
Steve Kinsey, Ph.D.
Li nda Klumpers, Ph.D.
George Kunos, M.D., Ph.D.
Aron Li chtman, Ph.D.
Alessi a Li gresti , Ph.D.
David Lovi nger, Ph.D.
Mary Lynch, Ph.D.
Mauro Maccarrone, Ph.D.
Ken Mackie, M.D.
Giovanni Marsi cano, Ph.D.
John McPartland, D.O.
Saoirse O’Sullivan, Ph.D.
Pal Pacher, M.D., Ph.D.
Sachin Patel M.D., Ph.D.
Roger Pertwee, MA, D.Phi l., D.Sc.
Daniele Piomelli, Ph.D.
Ethan Russo, M.D.
Esther Shohami, Ph.D.
Katarzyna Starowicz, Ph.D.
Yossi Tam, D.M.D., Ph.D. (Presi dent and Chair)
Mario van der Stelt, Ph.D.
Mark Ware, MBBS, MRCP
Andreas Zimmer, Ph.D.

Equality, Diversity and Inclusion Committee
Wi ng- Sze (Vanessa) Ho, Ph.D., Chair
Damian Cohall, Ph.D.
Rebecca Craft, Ph.D.

Committee on Awards
Steve Kinsey, Ph.D., Chair
Aron Li chtman, Ph.D.
Sachin Patel, M.D., Ph.D.

Student Prizes Committee Chair
Steve Alexander, Ph.D.

Mechoulam Award Committee
Mary Abood, Ph.D.
Francis Barth, Ph.D.
Benjamin Cravatt, Ph.D.
Vincenzo Di Marzo, Ph.D.
Cecilia Hillard, Ph.D.
Allyn Howlett, Ph.D.
John Huffman, Ph.D.
George Kunos, M.D., Ph.D.
Gerard Le Fur, Ph.D.
Aron Lichtman, Ph.D.
Beat Lutz, Ph.D.
Ken Mackie, M.D.
Mauro Maccarrone, Ph.D.
Alex Makriyannis, Ph.D.
Roger Pertwee, M.A., D.Phil, D.Sc.
Daniela Parolaro, Ph.D.
Daniele Piomelli, Ph.D.
Raj Razdan, Ph.D.
Patti Reggio, Ph.D.
Murielle Rinaldi-C armona, Ph.D.
Natsuo Ueda, M.D., Ph.D.
Andreas Zimmer, Ph.D.

2021 ICRS Board of Directors

Executive Director
Melanie Kelly, Ph.D.
President
Yossi Tam, D.M.D., Ph.D.
President-ElectDavid Finn, Ph.D.
Past President
David Finn, Ph.D.
Secretary
Saoirse O’Sullivan, Ph.D.
Treasurer
Steve Kinsey, Ph.D.
International Secretary
Roger Pertwee, M.a., D.Phil, D.Sc.
Student Representative
Stevie Britch, Ph.D.
Grant PI
Sachin Patel, M.D., Ph.D.
Equality, Diversity, and Inclusion Representative
Vanessa Ho, Ph.D.
Society Publication Liason
Heather Bradshaw, Ph.D.
Newsletter Editor
Stephen P.H. Alexander, Ph.D.
Managing Director
Jason B. Schechter, Ph.D.

ICRS2021 Day 1 - Live From Jerusalem
Monday, June 21st
07.00 EST
11.00 UTC

Welcome to ICRS2021: Opening Remarks

14.00 Local

07.00 – 09.00
11.00 – 13.00

Poster Session 1

P1

14.00 – 16.00

Oral Session 1. Endocannabinoid
Regulation and Signaling
Moderators: Cecilia Hillard, Ph.D. and Todd Stollenwerk

Veronika Kondev*,
Yulong Li, Ao Dongand Sachin PatelUTILIZING A NOVEL
ENDOCANNABINOID BIOSENSOR
TO ELUCIDATE CIRCUIT-SPECIFIC
ENDOCANNABINOID REGULATIONOF VENTRAL HIPPOCAMPUSBASOLATERAL AMYGDALA

1

09.15
13.15
16.15

Tamás Bíró*,Koji Sugawara, Nóra
Zákány, Stephan
Tiede, Talveen Purba,
Matthew Harries,
Daisuke Tsuruta
and Ralf Paus

HUMAN EPITHELIAL STEM CELLSURVIVAL WITHIN THEIR NICHEREQUIRES “TONIC” CB1-SIGNALING –LESSONS FROM THE HAIR FOLLICLE

2

09.30
13.30
16.30

Dorit Farfara*, Ben
Korin, Hytham Hajjo,
Hilla Azulay-Debby,
Liron Sulimani, Gil M.
Lewitus, Asya Rolls
and David Meiri

CHARACTERIZATION OF MOUSE
BRAIN ENDOCANNABINOID
DYNAMICS IN CIRCADIANRHYTHMICITY AND SLEEP ONSET

3

09.00
13.00
16.00

Heather Bradshaw*,
Clare Johnson,
Gabriel H.D. de Abreu,
Ken Mackie
and Hui-Chen Lu

CANNABINOID EXPOSURE DURINGLACTATION SIGNIFICANTLYCHANGES THE LIPID CONTENT
OF BREAST MILK INCLUDING THE
ENDOCANNABINOIDSANANDAMIDE AND 2-AG

4

10.00
14.00
17.00

Ao Dong*, Kaikai He,
Barna Dudok, Jordan S
Farrell, Wuqiang Guan,
Daniel J Liput, Henry L
Puhl, Ruyi Cai, Jiali
Duan, Eddy Albarran,Jun Ding, David M
Lovinger, Bo Li, Ivan
Soltesz and Yulong Li

A FLUORESCENT SENSOR FORSPATIOTEMPORALLY RESOLVED
ENDOCANNABINOID DYNAMICS
IN VITRO AND IN VIVO

5

10.15
14.15

Bogna M IgnatowskaJankowska*,
Aysen Gurkan-Ozer,
Alexander Kuck, MicahJ Niphakis, Daisuke
Ogasawara, Benjamin F
Cravatt and Marylka
Yoe Uusisaari

DISTINCT KINEMATIC
CHARACTERISTICS OF MAGL
AND FAAH INHIBITION IN HIGHPRECISION 3D MOTION CAPTUREANALYSIS OF FREELYBEHAVING MICE

6

Francesca Palese*,
Silvia Pontis, Natalia
Realini, Massimiliano
Lanfranco,Andrea Armirottiand Daniele Piomelli

TARGETING NAAA COUNTERS
DOPAMINE NEURON LOSSAND SYMPTOM PROGRESSION
IN A MOUSE MODEL OF
PARKINSON’S DISEASE

7

09.45
13.45
16.45

17.15

10.30
14.30
17.30

ICRS Presidential Plenary Lecturer

10.45 – 11:30
14.45 – 15:30
17.45 – 18:30

A CANNABINOID LINK BETWEEN BRAIN
BIOENERGETICS AND BEHAVIOR
Giovanni Marsicano, DVM, Ph.D.
Deputy Director, NeuroCentre Magendie
U1215 INSERM and Université Bordeaux, FranceEPM Sponsored Session

CANNABINOID ESTERS
11.30 – 12.00
15.30 – 16.00
18.30 – 19.00

EFFECT OF CANNABIDIOLIC ACID DERIVATIVE IN
TREATING DIET-INDUCED OBESITY
Elad Ben-Cnaan*, Anna Permyakova, Shahar Azar,
Shira Hirsch, Liad Hinden and Joseph Tam
METHYL ESTER CANNABINOIDS ARE POTENT ANTIINFLAMMATORY COMPOUNDSDan Peer*

Oral Session 2. CB2 Pharmacology and Signaling
Moderators: Rafael Maldonado, M.D., Ph.D. and Elena Martín-García, Ph.D.

Kishore Aravind
Ravichandran, Nico
Reusch, Bolanle Fatimat
Olabiyi, Joanna
Komorowska-Müller,
Jan N. Hansen, Thomas
Ulas, Marc Beyer,
Andreas Zimmer andAnne-Caroline Schmöle*

INTERACTION BETWEEN CB2 AND
TOLL-LIKE RECEPTORS SHAPESMICROGLIAL ACTIVITY

8

12.15
16.15
19.15

Samuel Ruiz de Martín
Esteban*, M. Teresa
Grande, Diego Herráez,
Rocío Palenzuela, Irene
Benito-Cuesta, Rosa M.
Tolón, Ricardo Mostany,
Cecilia J. Hillard
and Julián Romero

IN VIVO STUDIES OF THE ROLE OFCANNABINOID CB2 RECEPTORS IN
MICROGLIAL ACTIVITY IN AN
ANIMAL MODEL OF ALZHEIMER’SDISEASE BY MULTIPHOTONMICROSCOPY

9

12.30
16.30
19.30

Janos Paloczi*, Partha
Mukhopadhyay, Cody
Savage, Eszter Trojnár,
Csaba Matyas, Yuri
Persidsky, Uwe Grether
and Pal Pacher

TARGETED ACTIVATION, BUT
NOT INHIBITION OF CANNABINOID
RECEPTOR 2 (CB2R), IS A NOVELAPPROACH TO REDUCERENAL FIBROSIS

10

12.45
16.45
19.45

Hongfeng Deng*,
Clifton Leigh,Tama Evron, Ping
Zhang, Zhuang Jin
and Barbara WhiteDEVELOPMENT OF NOVEL
CB2 AGONISTS FOR TREATING
INFLAMMATORY ANDFIBROTIC DISEASES

11

12.00
16.00
19.00

13.0017.00
20.00

Idan Carmon*, Sai
Meka, Jinan Elayyan,
George Batshon, Eli
Reich, Andras BilkeiGorzo, Andreas Zimmer,
Raphael Mechoulam andMona Dvir-Ginzberg

13.15
17.15

HU308-MEDIATED CANNABINOID
SIGNALING MITIGATES AGE AND
TRAUMA-RELATED OSTEOARTHRITISIN MICE

12

Break

20.15

ICRS Lifetime Achievement Award

13.30 – 14.30
17.30 – 18.30
20.30 - 21.30

PRO-ADDICTION AND ANTI-ADDICTION EFFECTS OFCANNABINOIDS: QUELLE SURPRISE - DIFFERENTCANNABINOIDS HAVE DIFFERENT EFFECTS
Eliot Gardner Ph.D.

Senior Investigator
Molecular Targets and Medications Discovery Branch,
Neuropsychopharmacology Section, NIDA
Bethesda, MD USA

Oral Session 3. Cannabinoids
and Reward/Addiction
Moderators: Aron Lichtman, Ph.D. and Kennedy Goldsborough

14.30
18.30
21.30

Elena Martin-Garcia*,
Maria Cajiao,
Eric Senabre and
Rafael Maldonado

NEUROBIOLOGICAL MECHANISMS
UNDERLYING VULNERABILITY
AND RESILIENCE TO
CANNABIS ADDICTION

13

14.45
18.45

Samantha M. Ayoub*,
Reem Smoum, Mathew
Farag, Harkirat Atwal,
Cheryl L. Limbeer,
Erin M. Rock, Stephen
A. Collins, Fabiana
Piscitelli, Fabio Arturo
Iannotti, Vincenzo Di
Marzo, Francesco Leri,Aron H. Lichtman,
Raphael Mechoulam
and Linda A. Parker

THE EFFECT OF OLEOYL ALANINE ON
OPIOID WITHDRAWAL BEHAVIOURSIN MALE SPRAGUE DAWLEY RATS

14

21.45

15.00
19.00
22.00

15.15
19.15
22.15

15.30
19.30
22.30

Andrew J. Kesner*,
Stephanie RamosMaciel,
Yolanda Mateo,
Alexa L. Gracias
and David M. Lovinger

MODELING SPONTANEOUS THC
WITHDRAWAL SYMPTOMS IN MICE

15

Alexis F. League*,
Benjamin L. Gorman,
Ian R. Jacobs, Justin L.
Poklis, Micah J.
Niphakis, Benjamin F.
Cravatt, Aron H.
Lichtman, Bogna M.
Ignatowska-Jankowska
and Sylvia Fitting

INHIBITION OF
MONOACYLGLYCEROLLIPASE ALTERS DENDRITIC
BRANCHING COMPLEXITY
AND REWARD-RELATED BEHAVIORIN TAT TRANSGENIC MICE

16

Catharine A. Mielnik*,
Claudia Lutelmowski,
Ali Salahpour,
Heather Bradshaw
and Ruth Ross

MONOACYLGLYCEROL LIPASE(MAGL), BUT NOT FATTY AMIDEACID HYDROLASE, INHIBITION
EXACERBATES HYPERDOPAMINERGICPHENOTYPES IN DOPAMINE
TRANSPORTER-KNOCKOUT(DATKO) MICE

17

NIDA CAREER WORKSHOP PRESENTATION
15.45 – 17.00
19.45 – 21.00
22.45 – 24.00

15.45 – 17.00
19.45 – 21.00

BUILD UNIQUE EXPERTISE TO SUCCEED
CAREER TRANSITION AND INDEPENDENCE
Yu (Woody) Lin, PhD
Roger Sorensen, PhD, MPH
Sylvia Fitting, PhD

CHAT ROOMS OPEN FOR DISCUSSION

22.45 – 24.00* Presenting author

Day 2
Tuesday, June 22nd
07.00 EST
11.00 UTC
14.00 Local

07.00 – 09.00
11.00 – 13.00

Welcome to ICRS2021: Opening Remarks

Poster Session 2

P2

14.00 – 16.00

Oral Session 4. CB1 Pharmacology and Signaling
Moderators: George Kunos, M.D., Ph.D. and Malliga Iyer, Ph.D.

09.00
13.00
16.00

09.15
13.15
16.15

09.30
13.30
16.30

Ariel Rothner*, Liad
Hinden, Majdoleen
Ahmad, Alina
Nemirovski, Ifat
Abramovich, Bella
Agranovich, Aviram
Kogot-Levin, Eyal
Gottlieb, Gil Leibowitz
and Joseph Tam

THE DELETERIOUS ROLE OFCANNABINOID-1 RECEPTOR IN
THE PROGRESSION OF ACUTE
TO CHRONIC KIDNEY DISEASE

18Mark B. Wiley* andNicholas V. DiPatrizio

CB1 RECEPTORS IN THE
INTESTINAL EPITHELIUM ARE
PROTECTIVE AGAINST GUTBARRIER DYSFUNCTION IN
DIET INDUCED OBESITY

19

Anna VázquezOliver*, Silvia PérezGarcía, Nieves Pizarro,
Lydia Garcia-Serrano,
Gabriela Bordeanu,
Pier-Vincenzo Piazza,
Rafael De la Torre,
Rafael Maldonado
and Andrés Ozaita

CANNABINOID TYPE-1 RECEPTORINHIBITION AS A LONG-TERM
PHARMACOLOGICAL APPROACH
FOR MEMORY ENHANCEMENT IN A
MOUSE MODEL OF DOWN SYNDROME

20

09.4513.45
16.45

Richard C. Kevin*,
Elizabeth A. Cairns,
Samuel D. Banister,Michelle Glass,Mark Connor
and Iain S. McGregor

PRO-CONVULSANT SYNTHETICCANNABINOID RECEPTORAGONISTS: PHARMACOLOGICALAND TOXICOLOGICALASSESSMENT, AND IN VIVOEVALUATION OF FIRST-LINE
EMERGENCY TREATMENTS

21

10.00
14.00
17.00

Chloé Buch*, Tania
Muller, Julia Leemput,
Patricia PassillyDegrace, Pablo
CANNABINOID-1 RECEPTORS (CB1R)
Ortega-Deballon, Jean- MODULATE WHITE ADIPOSE TISSUE
LIPOLYSIS IN LEAN BUT NOT INPaul Pais de Barros,
OBESE RODENT AND HUMAN
Bruno Vergès,
Tony Jourdan,
Laurent Demizieux
and Pascal Degrace

22

10.15
14.15
17.15

Liad Hinden*,Majdoleen Ahmad,
Sharleen Hamad, Alina
Nemirovski, Gergő
Szanda, Sandra
Glasmacher, Aviram
Kogot-Levin, Bernard
Thorens, Jürg Gertsch,
Gil Leibowitz
and Joseph Tam

THE OPPOSING ROLE OF CB1
RECEPTOR IN MODULATINGRENAL PROXIMAL TUBULE
MTORC1 SIGNALING

23

10.30
14.30
17.30

Saja Baraghithy* Yael
Soae, Dekel Assaf,
Liad Hinden, Shiran
Udi, Adi Drori,
Yankel Gabet
and Joseph Tam

RENAL PROXIMAL TUBULE CELLCANNABINOID-1 RECEPTORREGULATES BONE REMODELINGAND MASS VIA AKIDNEY-TO-BONE AXIS

24

10.45
14.45
17.45

Break

William A Devane Young Investigator Award Speaker

11.00 – 11.30
15.00 – 15.30
18.00 – 18.30

DRILLING DOWN ON “CANNABIS”
IN THE HUMAN LABORATORY
Ryan Vandrey, Ph.D.

Professor of Psychiatry and Behavioral Sciences
Johns Hopkins Bayview Medical Center, Behavioral Biology
Research Center, Baltimore, Maryland, USA

Oral Session 5. Pain, Learning & Memory, Neuropathology
Moderators: David Finn., Ph.D. and Stephanie Bourke

11.30
15.30
18.30

Charlotte Piette*,
Sylvie Perez andLaurent Venance

THE ENDOCANNABINOID SYSTEMGATES FAST LEARNING

25

11.45
15.45

Rocío Palenzuela*,Gonzalo Ruiz-Pérez,Sharai Marqués, Noelia
Aparicio, M. Teresa
Grande, Irene BenitoCuesta, Ana M.
Martínez-Relimpio,
Samuel Ruiz de Martín
Esteban, María Posada,
Rosa M. Tolón,
Benjamin F. Cravatt,
José A. Esteban
and Julián Romero

ENDOCANNABINOID-MEDIATED
MODULATION OF NEURON-GLIA
CROSSTALK REVERSESNEUROPATHOLOGY IN A MOUSE
MODEL OF ALZHEIMER'S DISEASE

26

Marta Bryk*,
Jakub Mlost,
Serena Boccella,
Monica Iannotta,
Rosmara Infantino,
Sabatino Maione andKatarzyna Starowicz

MODULATION OF
ENDOCANNABINOID SIGNALING
IN THE HIPPOCAMPUS BY
CHRONIC PAIN

27

Eric S. Levine* andFouad Lemtiri-Chlieh

ENDOCANNABINOID-MEDIATED
ENHANCEMENT OF HIPPOCAMPALLONG-TERM POTENTIATION

28

18.45

12.00
16.00
19.00

12.15
16.15
19.15

12.30
16.30
19.30

12.45
16.45
19.45

Lia P. Iglesias*,
Carlos Sorgi and
Fabricio A. Moreira

ROLE OF HIPPOCAMPAL TRPV1
CHANNELS IN MEMORY:A TRPV1-CB1 BALANCE

29

Pascal Vogiaridis
and Steve Alexander*

HOW DANGEROUS ARE SYNTHETICCANNABINOID RECEPTORAGONISTS?

30

13.00
17.00

Break

20.00

Kang Tsou Memorial Speaker

13.15 – 14.15
17.15 – 18.15
20.15 - 21.15

SMALL RNA FINE TUNERS OF THE CHOLINERGICNETWORK IN HEALTH AND DISEASE
Hermona Soreq, Ph.D.

Slesinger Chair in Molecular Neuroscience
Hebrew University, Jerusalem, Israel

Oral Session 6. Cannabis Human Studies - Part 1
Moderator: Ziva cooper., Ph.D.

14.15
18.15
21.15

14.30
18.30
21.30

Kevin F. Boehnke*,
Joel J. Gagnier,Lynne Matallana
and David A. Williams

SUBSTITUTINGCANNABIDIOL FOR OPIOIDSAND PAIN MEDICATIONSAMONG INDIVIDUALSWITH FIBROMYALGIA:A LARGE ONLINE SURVEY

ABSTRACT WITHDRAWN

31

32

14.4518.45
21.45

Maja Kalaba, Erica Peters,
Chanez N. Kebacheand Mark A. Ware*

GLOBAL ADVERSEEVENTS AMONGCANNABIS USERS
IN 2020

33

15.00
19.00
22.00

Lucile Rapin*, Cynthia El
Hage, Maria-Fernanda
Arboleda, Michael Dworkind
and Erin Prosk

CANNABIDIOL
EFFECTIVENESS ONSYMPTOM BURDEN:
A RETROSPECTIVEOBSERVATIONAL STUDYON CANADIAN PATIENTS

34

Staci A. Gruber*, Ashley M.
Lambros, Rosemary T. Smith,
Kelly A. Sagar
and M. Kathryn Dahlgren

FOUR WEEKS OF
TREATMENT WITH A PLANTDERIVED, FULL-SPECTRUM
HIGH-CANNABIDIOL
PRODUCT FOR ANXIETY:RESULTS FROM AN OPENLABEL CLINICAL TRIAL

35

Ethan Russo*, Chris Spooner,
Len May, Ryan Leslieand Nishi Whiteley

CANNABINOID
HYPEREMESIS SYNDROMESURVEY AND GENOMIC
ASSESSMENT

36

15.15
19.15
22.15

15.30
19.30
22.30

15.45 – 17.00
19.45 – 21.00

CHAT ROOMS OPEN FOR DISCUSSION

22.45 – 24.00* Presenting author

Day 3
Wednesday, June 23rd
07.00 EST
11.00 UTC
14.00 Local
07.00 – 09.00
11.00 – 13.00

Welcome to ICRS2021: Opening Remarks

Poster Session 3

P3

14.00 – 16.00

Oral Session 7. Cannabidiol and Phytocannabinoids
Moderators: Alessia Ligresti, Ph.D. and Ali Mokhtar Mahmoud, Ph.D.

09.00
13.00
16.00

Lyndsey L. Anderson,
Marika Heblinski,
Nathan L. Absalom,
Nicole A. Hawkins,
Somayeh Mirlohi,
Michael Bowen, Michael
Udoh, Melissa J. Benson,
Fan Zhang, Dilara
Bahceci, Peter T.
Doohan, Chris Bladen,
Mark Connor, Mary
Chebib, Iain S.
McGregor,
Jennifer A. Kearney
and Jonathon C. Arnold*

PHYTOCANNABINOID ACIDSDISPLAY ANTICONVULSANT
ACTIVITY IN A MOUSE MODEL
OF DRAVET SYNDROME

37

09.15
13.15
16.15

Sigal Liraz-Zaltsman*,Chen Shemesh, Ruben
Sachsse, Yael FriedmanLevi, David Last,
Shirley Sharabi,
Yael Mardor,
Raphael Mechoulam
and Esther Shohami

THE EFFECTS OF CANNABIDIOL ON
THE RECOVERY OF MICE AFTERTRAUMATIC BRAIN INJURY

38

09.30
13.30
16.30

ABSTRACT WITHDRAWN

39

Sara Jane Ward*,
William A. Kinney
and Douglas E.
Brenneman

BEHAVIORAL AND
PHARMACOLOGICAL EFFECTS OFCANNABIDIOL (CBD) AND THE CBDANALOGUE KLS-13019 IN MOUSE
MODELS OF PAIN AND
REINFORCEMENT

40

10.00
14.00
17.00

Michael Udoh*,
Iain McGregor,Mark Connor andJonathon C. Arnold

CBGVA INHIBITS RECOMBINANT
HUMAN T-TYPE CALCIUM CHANNELS

41

10.15
14.15
17.15

Sarah H. Shrader*,Nicholas Mellen,
Gregory Barnes
and Zhao-Hui SongCANNABIDIOL ALTERS SOCIAL AND
REPETITIVE BEHAVIORS IN A MODEL
OF IDIOPATHIC AUTISM SPECTRUM
DISORDERS

42

10.30
14.30

Nicholas Dopkins*,
Kiesha Wilson,
Kathryn Miranda,
Prakash Nagarkatti
and Mitzi Nagarkatti

CANNABIDIOL TREATMENT IN
EXPERIMENTAL AUTOIMMUNEENCEPHALOMYELITIS INHIBITSPRODUCTION OF THE PRO
INFLAMMATORY CYTOKINE IL-1Β

43

Lucy J. Sloan*, Wei
Liang, Max Duff,
Sarah Shrader,
Yongqing Liu andZhao-Hui SongCANNABIDIOL INHIBITSANGIOGENIC PROCESSES IN
RETINAL MICROVASCULAR
ENDOTHELIAL CELLS

44

09.45
13.45
16.45

17.30

10.45
14.45
17.45

11.00
15.00
18.00

Break

ICRS Presidential Plenary Lecturer

ENDOCANNABINOID SYSTEM: AN UP-AND-COMING
11.15 – 12.15
15.15 – 16.15
18.15 – 19.15

SOURCE OF TARGETS FOR OSTEOARTHRITIS TREATMENT
Katarzyna Starowicz, Ph.D.

Institute of Pharmacology of thePolish Academy of Sciences
Kraków, Poland

Oral Session 8. Cannabinoid Drug Development & Delivery
Moderators: Ruth Ross, Ph.D. and Claudia Lutelmowski

12.15
16.15
19.15

Benoit Hornsperger, Jörg
Benz, Michael Honer,
Carsten Kroll, Bernd
Kuhn, Fionn O’Hara,
Andrea Martella,
Catarina Raposo, Hans
Richter, Manfred
Schneider, Juliane
Stephanus, Mario vander Stelt, Matthias
Wittwer, Ludovic Collin
and Uwe Grether*

DISCOVERY OF REVERSIBLE HIGHLY
POTENT AND SELECTIVE
BICYCLOPIPERAZINE DERIVEDMAGL INHIBITORS

45

12.30
16.30

Shira Hirsch*,
Meital Naim,
Gershon Golomb
and Joseph Tam

ENCAPSULATION OF A CENTRALLYACTING CANNABINOID-1 RECEPTOR(CB1R) BLOCKER IN PLGA-BASEDNANOPARTICLES FOR THE
TREATMENT OF NON-ALCOHOLIC
FATTY LIVER DISEASE

46

12.45
16.45
19.45

Thomas F. Gamage*,
Daniel Barrus andJenny L. Wiley

OPTIMIZATION OF TRUPATH BRET2ASSAY AND CHARACTERIZATION OF
CB1 RECEPTOR LIGANDS FOR G
PROTEIN SUBTYPE-SPECIFIC
ACTIVATION

47

13.00
17.00
20.00

Noam Freeman*, Ozer
Greenfield, Meital
Naim, Yael Soae, Amit
Badihi, Joseph Tam,
Taher Nassar andSimon Benita

POTENTIAL PERIPHERALLYRESTRICTED CANNABINOID-1
RECEPTOR BLOCKERS BASED ON
A BICYCLIC SCAFFOLD

48

13.15
17.15
20.15

Reem Smoum*,
Christeene Haj, Shira
Hirsch, Zhannah
Yekhtin, Ruth Gallily,
Joseph Tam andRaphael Mechoulam

FENCHONE DERIVATIVES:A NOVEL CLASS OF CB2 RECEPTOR
SELECTIVE LIGANDS

49

19.30

13.3017.30
20.30

Evangelos Dadiotis*,
Vangelis Mitsis,
Eleni Melliou andProkopios Magiatis

DIRECT QUANTITATION OF
PHYTOCANNABINOIDS BY ONEDIMENSIONAL 1H qNMR AND TWODIMENSIONAL 1H-1H COSY qNMR INCOMPLEX NATURAL MIXTURES

50

13.45
17.45

Antonius P. A.
Janssen*, Johanna G.
Bovenberg, Gerard
J.P. van Westen andMario van der Stelt

COMPUTATIONAL DE NOVO DRUG
DESIGN: AN APPLICATION OF A
RECURRENT NEURAL NETWORKMODEL TRAINED THROUGH
REINFORCEMENT LEARNING TO THE
CASE OF CB2-RECEPTOR AGONISTS

51

20.45

14.00
18.00

Break

21.00

ICRS Mechoulam Award Speaker

14.15 – 15.15
18.15 – 19.15
21.15 - 22.15

MY ENZYMOLOGICAL STUDIES ON
ENDOCANNABINOIDS AND RELATED
N-ACYLETHANOLAMINES
Natsuo Ueda, M.D., Ph.D.

Professor of Biochemistry
Kagawa University School of Medicine, Japan

Oral Session 9. Cannabinoid Interactions with Drugs of Abuse
Moderators: Matthew Hill, Ph.D. and Catherine Hume, Ph.D.

15.15
19.15
22.15

Grzegorz Godlewski*,
Luis Santos Molina,
Resat Cinar,
Jie Liu, Malliga Iyer
and George Kunos

PERIPHERAL HYBRID
CB1 RECEPTOR/INOSANTAGONIST MRI 1867
REDUCES ALCOHOLDRINKING BEHAVIOR AND
SOME INFLAMMATORY
MARKERS IN THE GI TRACT52

INHIBITION OF FATTY ACIDAMIDE HYDROLASE IN THE
CNS PREVENTS AND
REVERSES MORPHINETOLERANCE IN MALE
AND FEMALE MICE

15.30
19.30
22.30

Yannick Fotio*, Francesca
Palese, Pablo Guaman Tipan,
Faizy Ahmedand Daniele Piomelli

15.45
19.45
22.45

Ewa Galaj*, Guo-Hua Bi,
OF PIMSR1, A NOVEL CB1
Allamar Moore, Eliot Gardner, NEUTRAL ANTAGONIST, FOR
COCAINE USE DISORDER:
Herbert Seltzman
EVIDENCE FROM
and Zheng-Xiong Xi

54

Grzegorz Godlewski*,
Luis Santos Molina, Resat
Cinar, Jie Liu, Malliga Iyer
and George Kunos

CB1 RECEPTORS ONSENSORY AFFERENTS OF THE
GASTROINTESTINAL TRACT
MAY CONTRIBUTE TO THE
CONTROL OF VOLUNTARY
ALCOHOL DRINKINGIN MICE

55

Julien C. Dodu*, Rebecca K.
Moncayo, Aiden Jones, Joel E.
Schlosburg, M. Imad Damaj,
Dai Lu, Debra Kendall
and Aron H. Lichtman

THE CB1 POSITIVE
ALLOSTERIC MODULATOR,ZCZ011, ATTENUATESNALOXONE-PRECIPITATEDWITHDRAWAL SIGNS INOXYCODONE-DEPENDENT
MICE

56

53

THERAPEUTIC POTENTIAL

PRECLINICAL RESEARCH

16.00
20.00
23.00

16.15
20.15
23.15

16.30 – 17.00
20.30 – 21.00

CHAT ROOMS OPEN FOR DISCUSSION

23.30 – 24.00* Presenting author

Day 4Thursday, June 24th
07.00 EST
11.00 UTC

Welcome to ICRS2021: Opening Remarks

14.00 Local

07.00 – 09.00
11.00 – 13.00
14.00 – 16.00

Poster Session 4P4Oral Session 10. Cannabis Human Studies - Part 2Moderators: David Meiri, Ph.D. and Iris Wyrobnik

09.00
13.00
16.00

Colleen Trevino,
Aniko Szabo, Terri A.
deRoon-Cassiniand Cecilia J. Hillard*

CIRCULATING CONCENTRATIONS
OF THE ENDOCANNABINOID,
2-ARACHIDONOYLGLYCEROL, AT
TIME OF TRAUMATIC INJURY AREASSOCIATED WITH CHRONIC PAIN

57

09.15
13.15
16.15

Erica N. Peters*, Irina
MULTIPLE-DOSE STUDY TO
Mosesova, LauraEVALUATE THE SAFETY,
MacNair, Ryan
TOLERABILITY, PHARMACOKINETICS,
Vandrey, M. Hunter
AND PHARMACODYNAMICS OF
Land, Mark A. Ware,
SPECTRUM YELLOW OIL IN HEALTHY
Cynthia Turcotte and
PARTICIPANTS
Marcel O. Bonn-Miller

58

09.30
13.30
16.30

Jennifer Spohrs*,
Laura Bindila,Michael Prost, Paul
Plener, Georg Groen,
Birgit Abler andMartin Ulrich

59

FAAH GENETIC VARIATIONMODULATES NEURAL CORRELATESOF EXTINCTION RECALL –AN FMRI STUDY09.4513.45
16.45

Elyad Davidson*,
Ester Goldberg,
Salhab Kalil
and Josh Schroeder

EFFECT OF A CANNABIS EXTRACT ON
ACUTE RADICULAR PAIN AND ON
ANALGESICS REQUIREMENT: A
DOUBLE-BLINDED, RANDOMIZED,24 HOURS FOLLOW-UP STUDY

60

10.00
14.00
17.00

Vered Hermush*, Liora
Ore, Noa Stern, Nisim
Mizrahi, Malki Fried,
Marina Krivoshey,
Ella Staghon, Violeta
E. Lederman and Lihi
Bar-Lev Schleider

CANNABIDIOL OIL FOR BEHAVIORALDISTURBANCES IN DEMENTIA, A
DOUBLE-BLIND, RANDOMIZED,PLACEBO-CONTROLLED
CLINICAL TRIAL

61

10.15
14.15
17.15

Xintian Lyu*, Silvia
Illamola, Stephen
Dahmer, Paloma
Lehfeldt, Ilo Leppik
and Angela Birnbaum

DOSAGE AND FORMULATIONSRECEIVED BY PATIENTS WITHIN A
US STATE CANNABIS PROGRAM

62

10.30
14.30

Break

17.30

ICRS Presidential Plenary Lecturer

10.45 – 11.45
14.45 – 15.45
17.45 – 18.45

CANNABIS AND NEURODEVELOPMENTAL
VULNERABILITY: WHAT DO WE REALLY KNOW
Yasmin Hurd, Ph.D.

Departments of Psychiatry,
Neuroscience and Pharmacology and Systems Therapeutics,
Ward-Coleman Chair of Translational Neuroscience
Director, Addiction Institute at Mount Sinai, NY, USA

Oral Session 11. Novel CB1 Modulators
Moderators: Steven Kinsey, Ph.D. and Olivia Vanegas

11.45
15.45
18.45

Resat Cinar* Ziyi Liu,
Malliga R. Iyer,
Grzegorz Godlewski,
Tony Jourdan, Jie Liu,
Nathan J. Coffey,
Charles N. Zawatsky,
Henry L. Puhl, Jeih-San
Liow, Robert B. Innis,
Sergio A. Hassan,
Yong-Sok Lee
and George Kunos

FUNCTIONAL SELECTIVITY OF A
BIASED CANNABINOID-1 RECEPTOR(CB1R) ANTAGONIST FOR ANTIDIABETIC EFFICACY WITHOUT CNS
SIDE-EFFECTS

63

12.0016.00
19.00

Sumanta Garai*,
Luciana M. Leo, AnnaMaria Szczesniak,
Dow P. Hurst, Peter C.
Schaffer, Ayat
Zagzoog, TallanBlack, Roger G.
Pertwee, Mary E.
Abood,
Melanie E. M. Kelly,
Patricia H. Reggio,
Robert B. Laprairieand Ganesh A. Thakur

DISCOVERY OF G-PROTEIN BIASED
CB1R ALLOSTERIC MODULATOR FOR
THE TREATMENT OF GLAUCOMAWITH LONG-DURATION OF ACTION

64

12.15
16.15

Asaad Gammal*,Anna Permyakova,
Naama Adi-Hen, Julie
Asfour, Amit Badihi,
Taher Nassar, Simon
Benita and Joseph Tam

DUAL TARGETING OFCANNABINOID-1 RECEPTOR
AND MODULATION OF PPARa
ATTENUATES OBESITY-INDUCEDFATTY LIVER DISEASE

65

Malliga R. Iyer*,
Resat Cinar,
Charles Zawatsky,
Casey Wood, Nathan
J. Coffey, Kyu AhKim, Jasmina Abdalla,
Alexis Katz
and George Kunos

STUDIES ONPERIPHERALLY RESTRICTED
3,4-DIARYLPYRAZOLINES
AS POTENT ANTAGONISTS OFCANNABINOID-1 RECEPTOR (CB1R)

66

Tama Evron,Suzie Ferreira,
Hongfeng Deng,
Andrew Kolodziej*
and Barbara WhiteTHE DEVELOPMENT OF PERIPHERAL
CB1 INVERSE AGONISTS WITH
METABOLIC, ANTI-INFLAMMATORY,
AND ANTI-FIBROTIC ACTIVITIES

67

19.15

12.30
16.30
19.30

12.45
16.45
19.45

13.00
17.00
20.00

Break

ICRS Presidential Plenary Lecturer

13.15 – 14.15
17.15 – 18.15
20.15 – 21.15

EPIGENETICS: FROM PLURIPOTENTSTEM CELLS TO ANCIENT DNA
Eran Meshorer, Ph.D.

Arthur Gutterman Chair in Stem Cell Research,
Edmond and Lily Safra Center for Brain Sciences,
Hebrew University, Jerusalem, Israel

Oral Session 12. THC
Moderators: Pascal Degrace, Ph.D. and Tony Jourdan, Ph.D.

14.15
18.15
21.15

14.30
18.30
21.30

14.45
18.45
21.45

Clare Diester*, James
Gillespie, Hallie Lappin,
Aron Lichtman,
Dana Selley,
Laura Sim-Selley
and Steve Negus

EFFECTS OF
ENDOCANNABINOID
CATABOLIC ENZYMEINHIBITORS AND ∆9TETRAHYDROCANNABINOLON ACUTE PAIN-DEPRESSEDNESTING IN MICE

68

Jacqueline-Marie N. Ferland*,Randall J. Ellis, Gregory
Rompala, Joseph A. Landry,James E. Callens, Annie Ly,
Micah Frier, Teddy Uzamere,
Graeme Betts,
Mason M. Silveira,Catharine A. Winstanley
and Yasmin L. Hurd

ADOLESCENT THC HAS
DOSE-DEPENDENT EFFECTS
ON REWARD, STRESSREACTIVITY, AND DECISION
MAKING IN ADULTHOOD
VIA PERTURBATIONS IN
ASTROCYTES

69

Kwang-Mook Jung*, Hye-lim
Lee, Erica Squire, Yannick
Fotio, Francesca Palese, Alexa
Torrens, Shiqi Su, Christina
Renee Wong, Lin, Lin Ll, Jade
Ramirez and Daniele Piomelli

PERSISTENT EFFECTS OF
FREQUENT ADOLESCENTTHC EXPOSURE ON SOCIALDEFEAT STRESS

70

15.0019.00
22.00

Marieka V. DeVuono*,
Olivia La Caprara, Megan T.
Sullivan, Alexandra Bath,Gavin N. Petrie, Erin M.
Rock, Cheryl M.
Limebeer, Matthew N. Hilland Linda A. Parker

THE ROLE OF THE
ENDOCANNABINOIDSYSTEM AND STRESS IN
CANNABINOID
HYPEREMESIS SYNDROME

71

15.15
19.15
22.15

Lin Lin*, Kwang-Mook Jung,
Steve Mahler, Faizy Ahmed,
Erica Squire, Shiqi Su, Alexa
Torrens, Yannick Fotio, Jade
Ramirez, Hyelim lee,Francesca Paleseand Daniele Piomelli

ADOLESCENT THCEXPOSURE PERMANENTLYREPROGRAMS ADIPOSE
ENERGY METABOLISM

72

Bryant Avalos*and Nicholas V. DiPatrizio

CHRONIC EXPOSURE TO
WHOLE CANNABISEXTRACTS AMELIORATESMETABOLIC DYSFUNCTIONASSOCIATED WITH DIETINDUCED OBESITY IN MICE

73

Hyelim Lee*, Erica Squire,
Yannick Fotio, Francesca
Palese, Alexa Torrens, Shiqi
Su, Cristina Wong, Lin Lin,
Jade Ramirez, Kwang-Mook
Jung and Daniele Piomelli

ADOLESCENT THCEXPOSURE PERSISTENTLY
SUPPRESSES MICROGLIAFUNCTION IN MICE

74

15.30
19.30
22.30

15.45
19.45
22.45

ICRS Founder’s Lecturer

16.00 – 16.40
20.00 – 20.40
23.00 – 23.40

AN OVERVIEW OF CANNABINOIDRESEARCH OVER ALMOST 60 YEARS
Raphael Mechoulam, Ph.D.

Professor Emeritus
Hebrew University of Jerusalem, Israel

16.40 –
20.40 –CHAT ROOMS OPEN FOR DISCUSSION

23.40 –* Presenting author

ICRS2021 POSTER SESSION TOPICS
P1 // Monday, June 21, 2021
07.00 – 09.00 EST // 11.00 – 13.00 UTC // 14.00 – 16.00 LOCAL
A. Endocannabinoid Regulation and Signaling
B. CB2 Pharmacology and Signaling
C. Cannabinoids and Reward/Addiction
LB. LATE-BREAKING RESEARCH

P2 // Tuesday, June 22, 2021
07.00 – 09.00 EST // 11.00 – 13.00 UTC // 14.00 – 16.00 LOCAL
D. CB1 Pharmacology and Signaling
E. Pain, Learning & Memory, Neuropathology
F. Cannabis Human Studies - Part 1

P3 // Wednesday, June 23, 2021
07.00 – 09.00 EST // 11.00 – 13.00 UTC // 14.00 – 16.00 LOCAL
G. Cannabidiol and Phytocannabinoids
H. Cannabinoid Drug Development & Delivery
I. Cannabinoid Interactions with Drugs of Abuse

P4 // Thursday, June 24, 2021
07.00 – 09.00 EST // 11.00 – 13.00 UTC // 14.00 – 16.00 LOCAL
J. Cannabis Human Studies - Part 2
K. Novel CB1 Modulators
L. THCPOSTER SESSION 1 – Topics A-C
DAY 1, Monday, June 21st
A. Endocannabinoid Regulation and Signaling
ABSTRACT WITHDRAWN

P1 - 1

Uma Anand*, Barbara Pacchetti,
Praveen Anandand Mikael H. Sodergren

INVESTIGATING CANNABINOIDENTOURAGE EFFECTS IN
CULTURED DRG NEURONS

P1 - 2

Luara A. Batista*, Thiago S.
Moreira and Ana C. Takakura

INHIBITION OF ANANDAMIDEHYDROLYSIS AS A STRATEGYTO COUNTERACT RESPIRATORYABNORMALITIES OBSERVED IN
AN ANIMAL MODEL OF
PARKINSON’S DISEASE

P1 - 3

Hagar Bauminger*,
Hiba Zaidan, Inna GaislerSalomon and Irit Akirav

ANANDAMIDE HYDROLYSISREVERSES THE PROLONGED
BEHAVIORAL AND GENE
EXPRESSION ALTERATIONSINDUCED BY ADOLESCENCENMDA RECEPTORHYPOFUNCTION

P1 - 4

Tallan Black*, Ayat Zagzoog,
Andrew Roebuck, Quentin
Greba, John G. Howland
and Robert B. Laprairie

CHARACTERIZATION AND
TARGETING OF THE
ENDOCANNABINOID SYSTEM IN
TRAUMATIC BRAIN INJURY

P1 - 5

Laura Boullon*, David P. Finn
and Alvaro Llorente-Berzal

SEX-DEPENDANT BRAINREGIONAL ALTERATIONS IN THE
ENDOGENOUS CANNABINOIDSYSTEM IN A RAT MODEL OFPERIPHERAL NEUROPATHIC PAIN

P1 - 6Elizabeth A. Cairns*, Dilini
Gunatilake, Adam Ametovski,
Lewis J. Martin, Jonathan C.
Arnold, Samuel D. Banister,
Iain S. McGregor
and Jessamy C. Tiffen

THE EXPRESSION OFCOMPONENTS OF THE
ENDOCANNABINOID SYSTEM
PREDICTS PATIENT SURVIVAL IN
MELANOMA BUT CANNABINOIDSLACK SELECTIVITY AS
POTENTIAL THERAPEUTICS

P1 - 7

Ian de Bus*, Sandra van
Krimpen, Han Zuilhof , Renger
Witkamp, Bauke Albada
and Michiel Balvers

CHARACTERIZATION AND
IMMUNE MODULATION OF COX2-DERIVED DHEA METABOLITESIN LPS-STIMULATED
MACROPHAGES

P1 - 8

Ian de Bus*, Twan America,
Norbert de Ruijter, Han Zuilhof,
Renger Witkamp, Bauke Albada
and Michiel Balvers

CHEMICAL ENDOCANNABINOIDDERIVED PROBES SUGGEST A
POTENTIAL REGULATING ROLE
IN RAC1 SIGNALLING

P1 - 9Ryan. R Hall*, Damian Cohall
and Andrew B. Tobin

CROSSTALK BETWEENMUSCARINIC RECEPTORSAND CANNABINOID RECEPTORS:IDENTIFYING POTENTIAL
THERAPIES IN TEMPORALLOBE EPILEPSY

P1 - 10

Mary Hopkins*, Ana Bagüés,
Yolanda López-Tofiño,
Raquel Abalo andAlvaro Llorente-Berzal

CHANGES IN THE
ENDOCANNABINOID SYSTEM
OF MALE RATS TREATED WITH
A SINGLE SUB-NOXIOUS DOSE
OF CISPLATIN

P1 - 11

Clare T Johnson*
and Heather B Bradshaw

GPR55 ANTAGONIST ML193 AND
AGONIST O-1602 HAVE CELL AND
TIME-DEPENDENT EFFECTS ON
LIPID REGULATION

P1 - 12

Rupali Vyawahare,
Ewa Wasilewski, Rex Siming
Wang and Lakshmi P. Kotra*

DIFFERENTIAL EFFECTS OFCANNABINOID RECEPTOR
LIGANDS ON THE PRODUCTION
OF CAMP IN MALE AND FEMALECELLS OF NEURONAL ORIGIN

P1 - 13

Gitit Kra*, Uzi Moallem, Radka
Kočvarová, Alina Nemirovski,
Joseph Tam, G. A. Contreras
and Maya Zachut

EFFECTS OF PERIPARTUMOMEGA-3 FATTY ACID
SUPPLEMENTATION ON
ENDOCANNABINOID TONE
AND INFLAMMATION IN
LIVER OF DAIRY COWS

P1 - 14

Gitit Kra*, Uzi Moallem,
Majdoleen Ahmad, Alina
Nemirovski, Joseph Tamand Maya Zachut

SEASONAL HEAT STRESSAFFECTS ENDOCANNABINOID
GENE EXPRESSION IN ADIPOSE
TISSUE OF POSTPARTUMDAIRY COWS

P1 - 15

Claudia Lutelmowski*,Catharine Mielnik, Ali
Salahpour, Amy J. Ramsey,
Heather B. Bradshaw, Marija
Milenkovic, Wendy Horsfall
and Ruth Ross

THE BEHAVIOURAL AND
LIPIDOMIC EFFECTS OF
INHIBITING ENDOCANNANINOIDMETABOLISM IN A HYPOGLUTAMATERGIC MODEL OF
PSYCHOSIS-LIKE PHENOTYPES

P1 - 16

Sara Standoli, Cinzia Rapino,
Camilla Di Meo
and Mauro Maccarrone*

EFFECT OF SPHINGOSINE-1PHOSPHATE ON
ENDOCANNABINOID SIGNALING

P1 - 17

Alessandra Piccirilli, Roberto
Coccurello, Sergio Oddi,
Mariagrazia Perilli
and Mauro Maccarrone*

EFFECT OF ULTRAMICRONIZEDPEA ON THE FAECALMICROBIOME OF A TRANSGENIC
MOUSE MODEL OFALZHEIMER’S DISEASE

P1 - 18

Alessandro Leuti, Marina Fava,
Niccolò Pellegrino
and Mauro Maccarrone*

ENDOCANNABINOIDS AND PRORESOLVING MEDIATORS ACTSYNERGICALLY IN PRIMARYHUMAN MACROPHAGES

P1 - 19

Chanté A. Muller*, Diane L.
Lynch, Dow P. Hurst
and Patricia H. Reggio

UNIQUE ENTRY OF
ANANDAMIDE AT TRPV1

P1 - 20

Gavin Petrie*, Georgia
Balsevich, Hiulan Yau, Tamas
Fuzesi, David Rosenegger,
Robert Aukema, Mario Van Der
Stelt, Jaideep Bainsand Matthew Hill

TONIC ENDOCANNABINOID
SIGNALLING GATES STRESS-LIKE
STEREOTYPIC BEHAVIORS AND
HPA AXIS ACTIVATION

P1 - 21

Erin M. Rock*, Cheryl L.
Limebeer, Reem Smoum,Raphael Mechoulam
and Linda A. Parker

EFFECT OF THE FATTY ACIDAMIDES OLEOYL GLYCINE AND
OLEOYL ALANINE ON LITHIUM
CHLORIDE-INDUCED NAUSEA IN
RATS AND VOMITING IN SHREWS

P1 - 22

Syed Haneef Syed Askar*,
Marina Santiago
and Mark Connor

COMPARISON OF THE
PHARMACOLOGY OF THE
HUMAN AND ZEBRAFISHCANNABINOID RECEPTORS

P1 - 23

B. CB2 Pharmacology and Signaling
Ana M. Martínez Relimpio*,
M. Teresa Grande, Samuel Ruizde Martín Esteban, M. Andrea
Arnanz, Rosa M. Tolón, Cecilia
J. Hillard and Julián Romero

A COMPREHENSIVE ANALYSIS OF
MICROGLIAL CANNABINOID CB2
RECEPTORS IN THE CONTEXT OFAMYLOID-INDUCEDNEUROINFLAMMATION

P1 - 24

Bolanle F. Olabiyi*,
Eike Geissmar, Andreas Zimmer
and Anne-Caroline Schmöle

THE METABOLIC SIGNATURE
OF CB2 IN LPS-INDUCEDMICROGLIA STRESS RESPONSE

P1 - 25

C. Cannabinoids and Reward/Addiction

Maria T Rivera-Garcia*
and Adrianne R Wilson-Poe

EFFECTS OF CANNABIS
VAPOR INHALATION IN
THE ESTABLISHMENTAND EXPRESSION OF
MORPHINE REWARD

P1 - 26

Samah Shahen-Zoabi*, Reem
Smoum, Tehila Beiser, Raphael
Mechoulam and Rami Yaka

N-OLEYOLGLYCINE AND ITSDERIVATIVES ATTENUATE THE
ACQUISITION AND EXPRESSION
OF COCAINE INDUCEDBEHAVIOURS

P1 - 27

S. Olivia Vanegas*,
Kristen R. Trexler
and Steven G. Kinsey

NOVELTY-INDUCEDHYPOPHAGIA AS A MEASURE OF
SPONTANEOUS CANNABINOID
WITHDRAWAL

P1 - 28

POSTER SESSION 2 – Topics D-F
DAY 2, Tuesday, June 22st

D. CB1 Pharmacology and Signaling
AyoOluwa O. Aderibigbe*,
Pankaj Pandey
and Robert J. Doerksen

KNOWN MOLECULAR SWITCHES AND
NEW GEOMETRIC DESCRIPTORS FOR
THE CANNABINOID RECEPTOR 1 (CB1)P2 - 1

Courtney A. Bouchet*,
Amy J Eshleman,
Aaron Janowsky
and Susan L. Ingram

CANNABINOID 1 RECEPTORFUNCTION IS REDUCED IN THE
VENTROLATERAL PERIAQUEDUCTALGRAY AFTER PERSISTENT
INFLAMMATION

P2 - 2

Sumner Burstein

INFLAMMATION-RESOLVINGACTIONS OF AJULEMIC ACID

P2 - 3

Nadia Di Franco*, Guillaume
Drutel, Valerie Lacarriere,
Valerie Lalanne, Nicole
Etchamendy, Agnes Grel,
Filippo Caraci, GiovanniMarsicano, Aline Marighetto,
Piervincenzo Piazza, Monique
Vallée and Jean-Michel Revest

CB1 AS A POTENTIAL TARGETFOR COGNITIVE DEFICITSIN DOWN SYNDROME

P2 - 4

Alessandra Gargano*,
Eva Beins, Andreas Zimmer
and Andras Bilkei-Gorzo

LACK OF CANNABINOID RECEPTOR
TYPE-1 LEADS TO ENHANCED AGERELATED NEURONAL LOSS IN THE
LOCUS COERULEUS

P2 - 5

Barbara L. F. Kaplan*, Brittany
Szafran, Ashleigh Nicaise,
Matthew K. Ross
and James Nichols

CB1 INACTIVATION INCREASES PROINFLAMMATORY CYTOKINEPRODUCTION IN RESPONSE TO
LIPOPOLYSACCHARIDE

P2 - 6

Hye Ji (Jay) Kim*,
Teagan Holt, Udoka Ezeaka
and Robert Laprairie

IN VIVO EVIDENCE FOR
FUNCTIONAL INTERACTIONSBETWEEN CANNABINOID AND
OREXIN RECEPTORS IN THE
ADULT MOUSE BRAIN

P2 - 7

Cristina Manenti*, Erica
Zamberletti, Marina Gabaglio
and Tiziana Rubino

THE ENDOCANNABINOID SYSTEM
IS A RELEVANT PLAYER INADOLESCENT MYELINATION

P2 - 8Madison N. Myers*, C. Javier
Rendon, Maya Zachut, Joseph
Tam and G. Andres Contreras

CANNABINOIDS MODULATEADIPOGENESIS AND LIPOGENESISIN DAIRY COWS

P2 - 9Alexis Papariello*,
David Taylor, Ken Soderstrom
and Karen Litwa

CB1 ANTAGONISM INCREASESEXCITATORY SYNAPTOGENESIS IN A
CORTICAL SPHEROID MODEL OFFETAL BRAIN DEVELOPMENT

P2 - 10

Richard Slivicki*, Jiwon Yi,
Victoria Brings, Phuong Huynh
and Robert Gereau IV

THE PERIPHERALLY RESTRICTEDCANNABINOID CB-13 PRODUCESPERIPHERALLY-MEDIATEDANALGESIA BUT REPEATEDDOSING ELICITS TOLERANCEAND SIGNS OF CENTRALNERVOUS SYSTEM ACTIVITY

P2 - 11Michelle St. Pierre*,
Sarah Daniels, Tatiana Sanchez
and Zach Walsh

VALIDATION OF THE NATURALISTICCANNABIS ADMINISTRATIONPROTOCOL (NCAP)

P2 - 12

Carsten C. F. Walker*
and Lorraine M. Sordillo

ANANDAMIDE ENHANCES BARRIER
INTEGRITY OF BOVINE VASCULAR
ENDOTHELIAL CELLS DURING
ENDOTOXIN CHALLENGE VIACANNABINOID RECEPTOR-1
ACTIVATION

P2 - 13

Courtney P. Wood*,
Pedro A. Perez
and Nicholas V. DiPatrizio

ROLE OF CANNABINOID RECEPTORSUBTYPE-1 IN THE INTESTINAL
EPITHELIUM IN ANXIETY-LIKE
BEHAVIORS

P2 - 14

Alexander Young*, Shawn
Adderley, Melanie Kelly
and Eileen Denovan-Wright

CANNABINOIDS MODULATE
THE PRO- AND ANTI-INFLAMMATORYPROPERTIES OF POLARIZED
M1/M2 MICROGLIA IN VITRO

P2 - 15

Charles Zawatsky*, Jasmina
Abdalla, George Kunos
and Resat Cinar

CANNABINOIDS INDUCE LUNG
INFLAMMATION VIA CB1R
ACTIVATION

P2 - 16

E. Pain, Learning & Memory, Neuropathology

Konstantin Andrianov*, Inna
Gaisler-Salomon and Irit Akirav

DOUBLE EXPOSURE TO STRESSAS A RISK FACTOR FOR SEVEREPSYCHIATRIC DISORDERS:
THE INVOLVEMENT OF
ENDOCANNABINOID MARKERS

P2 - 17

Geraint Berger*, Juan Zhou,
Melanie Kelly
and Lehmann Christian

INTRAVESICAL BETACARYOPHYLLENE AMELIORATESLPS-INDUCED BLADDERINFLAMMATION AND PAIN IN A
MURINE MODEL OF ACUTE CYSTITIS

P2 - 18

Henry Blanton*, Melissa
McHann, Kelsey Donckels,
Isabel Castro, Kevin Pruitt
and Josee Guindon

ACEA (CB1) AND CP55,940 (MIXED
CB1/CB2 ) SEX-SPECIFIC
ANTINOCICEPTIVE TOLERANCE IN
CHEMOTHERAPY-INDUCEDPERIPHERAL NEUROPATHY

P2 - 19

Erik J. Fleischel*and Sara Jane Ward

THE EFFECTS OF CANNABINOIDS IN
THE PREVENTION OF
CHEMOTHERAPY-INDUCEDNEUROPATHIC PAINP2 - 20

Kennedy Goldsborough*,Rebecca Moncayo, Lauren
Moncayo, Lesley D O' Brien,
Kalpna Gupta, M Imad Damaj,
Wally Smith, Joyce Lloyd
and Aron Lichtman

TARGETING MONOACYLGLYCEROLLIPASE TO REDUCE CHRONIC
PAIN IN A HUMANIZED MOUSE
MODEL OF SCD

P2 - 21

Bryan W. Jenkins*, Shoshana
Buckhalter, Melissa L. Perreault
and Jibran Y. Khokhar

IMPACT OF VAPOURIZEDCANNABIS CONSTITUENTS ON
OSCILLATORY ACTIVITY IN A
NEURODEVELOPMENTAL
MODEL OF SCHIZOPHRENIA

P2 - 22

Alex Mabou Tagne*, Yannick
Fotio, Lin Lin, Erica Squire,
Faizy Ahmed, Tarif Ibne
Rashid, Elnaz Karimian Azari
and Daniele Piomelli

HEMP OIL AND
PALMITOYLETHANOLAMIDE EXERTSYNERGISTIC ANTI-NOCICEPTIVEEFFECTS IN MOUSE MODELS OF
ACUTE AND CHRONIC PAINP2 - 23

Lesley D O'Brien*, Delaney
Place, Kimberley Karin, Jane
Roberts, David A Gewirtz,
M Imad Damaj
and Aron H Lichtman

TARGETING THE ENDOCANNABINOIDSYSTEM AS A STRATEGY TO ADDRESSAROMATASE INHIBITION-INDUCEDSELECTIVE DISRUPTION OFLEARNING AND MEMORY IN MICE

P2 - 24

Anna Portugalov*, Hiba
Zaidan, Inna Gaisler-Salomon
and Irit Akirav

INCREASING ANANDAMIDE LEVELSRESTORE DEPRESSION-LIKE
PHENOTYPE AND ALTERATIONSIN MICRO-RNAs IN RATS EXPOSEDTO EARLY LIFE STRESS

P2 - 25

Brenda Sbarski*, Eric Parise,
Eric Nestler and Irit Akirav

THE INVOLVEMENT OF Β-CATENIN
IN THE MEDIAL PFC IN PREVENTINGSTRESS-INDUCED EFFECTS IN A
RAT MODEL FOR PTSD

P2 - 26

Joshua A. Bilbrey, Yuma T.
Ortiz, Lance R. McMahon
and Jenny L. Wilkerson*

EVALUATION OF THE TERPENES
β-CARYOPHYLLENE, α-TERPINEOL,
AND γ-TERPINENE IN THE MOUSE
CHRONIC CONSTRICTION INJURY
MODEL OF NEUROPATHIC PAIN:
POSSIBLE CANNABINOID
RECEPTOR INVOLVEMENT

P2 - 27

F. Cannabis Human Studies - Part 1
ABSTRACT WITHDRAWN

Stephanie Bourke*, Therese O'
Connor, Nikita Burke, Massieh
Moayedi, Brian McGuireand David Finn

INVESTIGATING THE RELATIONSHIPBETWEEN AFFECTIVE STATE, STRESS,SOMATOSENSORY SENSITIVITY AND
CIRCULATING ENDOCANNABINOIDSIN HEALTHY HUMAN PARTICIPANTS:
A PILOT STUDY

P2 - 28

P2 - 29

Ana Gabriela Hounie, Marco
Agassiz Almeida Vasques andWilson da Silva Lessa Júnior*

CLINICAL EVOLUTION OF
TREATMENT OF PROGRESSIVESUPRANUCLEAR PALSY PATIENTWITH MEDICAL CANNABIS IN APERIOD OF TWELVE MONTHS

P2 - 30

M. Kathryn Dahlgren*, Kelly
A. Sagar, Ashley M. Lambros,
Rosemary T. Smith, Celine ElAbboud and Staci A. Gruber

VETERANS DEMOSTRATE IMPROVED
CLINICAL STATE AND HEALTHFOLLOWING SIX WEEKS OF
TREATMENT WITH A HIGHCANNABIDIOL PRODUCTP2 - 31

Simon Erridge*, Nagina
Mangal, Barbara Pacchetti
and Mikael H Sodergren

CANNFLAVINS – FROM PLANT TOPATIENT: A SCOPING REVIEW

P2 - 32

Samuel Hammond, Simon
Erridge*, Nagina Mangal,
Barbara Pacchetti
and Mikael Sodergren

THE EFFECT OF CANNABIS-BASEDMEDICINE IN THE TREATMENT OFCACHEXIA: A SYSTEMATIC REVIEWAND META-ANALYSIS

P2 - 33

Selina Espinoza*, Claudia
Rocha, Melissa-Ann Lagunas,
Courtney Crouse
and Jennifer L. Lovell

CANNABIS USE AND PERCEPTIONSAMONG COLLEGE STUDENTS
IN CALIFORNIA

P2 - 34

Nicholas Frane*, Erik
Stapleton, Cesar Iturriaga,
Maximillian Ganz, Rupa
Vijayan, Vijay Rasquinha
and Robert Duarte

CANNABIDIOL USE MAY BE
ASSOCIATED WITH IMPROVEMENTS
IN ARTHRITIS SYMPTOMATOLOGY:
AN EXPLORATORY CROSSSECTIONAL ANALYSIS

P2 - 35

Carsten Hjorthøj*,
Christine Merrild Posselt
and Merete Nordentoft

EVALUATION OF THE DANISH PILOTPROGRAM OF MEDICAL CANNABIS

P2 - 36

Christiana J. Smith, Daniela
Vergara, Brian C. Keegan
and Nick Jikomes*

THE CHEMOTYPE LANDSCAPE OF
COMMERCIAL CANNABIS IN THE
UNITED STATESP2 - 37

Minhi N. Kang*, Luisa
Bohorquez Montoya, Timothy
McAuliffe, Garrett Sauber,
Stacy A. Claesges, Cecilia J.
Hillard and Joseph S. Goveas

LONELINESS AND CIRCULATING
ENDOCANNABINOID
CONCENTRATIONS IN OLDERBEREAVED INDIVIDUALS

P2 - 38OBSERVED IMPACT OF LONG-TERM
CONSUMPTION OF ORALCANNABIDIOL ON LIVER FUNCTION
IN HEALTHY ADULTS

P2 - 39

Maureen Leehey*, Ying Liu,
Stefan Sillau, Sarah Fischer,
Jost Klawitter, Cristina Sempio,
TOLERABILITY AND EFFICACY OF
Michelle Fullard, Trevor
CANNABIDIOL ON MOTOR SYMPTOMS
Hawkins, Lauren Seeberger,
IN PARKINSON DISEASE: INTERIM
Emil Diguilio, David Vu, SarahREPORT ON TOLERABILITY
Baker, Tristan Seawalt, Grace
Chin and Jacquelyn Bainbridge

P2 - 40

Heike Newman,
Jacqueline L. Bainbridge
and Emily M. Lindley*

IMPLEMENTING CLINICAL TRIALSWITH CANNABIS PRODUCTS IN THE
UNITED STATES: CHALLENGES ANDLESSONS LEARNED

P2 - 41

Mallory Loflin*, Karisa Jaime,
Emily Wilhite, James Sottile,
Jillian Carter, Anisha Choi,
Shreya Sunkara
and Hannah Denton

PLACEBO EFFECT SIZES IN USREGISTERED CLINICAL TRIALS OF
CANNABIS AND CANNABINOID-BASEDINVESTIGATIONAL DRUGS:A SYSTEMATIC REVIEWAND META-ANALYSIS

P2 - 42Erin Martin*, Nathaniel Baker,
Brett Froeliger
and Aimee McRae-Clark

TOBACCO CO-USE INFLUENCES
TREATMENT OUTCOMES IN A PILOT
TRIAL OF VARENICLINE FORCANNABIS USE DISORDER

P2 - 43

Violaine Mongeau-Pérusse*,
Élie Rizkallah, Florence
Morissette, Suzanne Brissette,
Julie Bruneau, Simon
Dubreucq, Guillaume Gazil
and Didier Jutras-Aswad

CANNABIDIOL EFFECTS ON
ANANDAMIDE LEVELSIN INDIVIDUALS WITH COCAINEUSE DISORDER; EXPLORATORYRESULTS FROM A RANDOMIZEDCONTROLLED TRIAL

P2 - 44

Conor H. Murray*, Sissi
Huang, and Harriet de Wit

CANNABIS & YOUTH: ACUTE EFFECTS
OF THC ON ADOLESCENTS

P2 - 45

Timna Naftali

CANNABIS FOR THE TREATMENT OF
INFLAMMATORY BOWEL DISEASE –CURRENT EVIDENCE AND PROSPECT
FOR THE FUTURE

P2 - 46

Robert Kaufmann*,Keith Aqua, Jeff Lombardo
and Martin Lee

Elisa Pabon* and Harriet de Wit

EFFECTS OF MENSTRUAL CYCLE
PHASE AND CIRCULATINGESTRADIOL ON RESPONSE TO ORALDELTA-9-TETRAHYDROCANNABINOL

P2 – 47

Erin Prosk*, Gamaoun Rihab,
Cynthia El Hage,
Maria-Fernanda Arboleda
and Antonio Vigano

THE CBD CRAZE: MAKING A CASE
FOR OBSERVATIONAL CLINICALDATA TO ASSESS MEDICAL CANNABISTREATMENT EFFECTIVENESS

P2 – 48

Ethan Russo*, Carrie Cuttler,
Michelle Sexton
and Amanda Stueber

SURVEY OF PATIENTS EMPLOYINGCANNABIGEROL-PREDOMINANT
PREPARATIONS WITH CLINICALRESPONSES AND ADVERSE EVENTS

P2 - 49

Kelly Sagar*, M. Kathryn
Dahlgren, Rosemary Smith,Ashley Lambros, Celine ElAbboud and Staci Gruber

REPORTED SIDE EFFECTS AND
IMPRESSION OF CHANGE
FOLLOWING THREE MONTHS OF
MEDICAL CANNABIS TREATMENT

P2 - 50

Nir Treves*, Noa Mor,
Matitiahu Berkovitch,
Orit Stolar and Ilan Matok

EFFICACY AND SAFETY OF MEDICALCANNABIS IN THE PEDIATRICPOPULATION – SYSTEMATIC REVIEWAND META-ANALYSIS

P2 - 51

Barry Laird,
Andrew Yates*
and Steve D Reich

CANCER APPETITE RECOVERYSTUDY (CARES): STUDY PROTOCOLFOR A DOSE-ASCENDING,
MULTICENTER, RANDOMIZEDCONTROLLED PHASE 1/2 TRIAL OF
ART27.13 IN PATIENTS WITH CANCER
ANOREXIA AND WEIGHT LOSS

P2 - 52* Presenting author

POSTER SESSION 3 – Topics G-I
DAY 3, Wednesday, June 23nd

G. Cannabidiol and Phytocannabinoids
Osnat Almogi-Hazan*
and Reuven Or

CANNABINOIDS/CANNABIS ANDIMMUNITY - LESSONS FROM
PRE-CLINICAL STUDIES

P3 - 1

Clara Andradas*, Jacob Byrne,
Mani Kuchibhotla, Mathew
Ancliffe, Anya Jones, Brooke
Carline, Hilary Hii, Alexandra
Truong, Lisa Storer, Timothy
Ritzmann, Richard Grundy,
Nicholas Gottardo
and Raelene Endersby

ASSESSMENT OF CANNABIDIOLAND D9-TETRAHYDROCANNABINOLIN MOUSE MODELS OF
MEDULLOBLASTOMAAND EPENDYMOMA

P3 - 2

Daniel G. Barrus*, Thomas F.
Gamage and Jenny L. Wiley

PHARMACOLOGICAL
CHARACTERIZATION OF
PHYTOCANNABINOIDS AT HUMANCANNABINOID RECEPTORS

P3 - 3

ATTENUATION OF OXIDATIVE STRESSAND INFLAMMATORY RESPONSE BY
Patrycja Bielawiec*,
CHRONIC CANNABIDIOL
Ewa Harasim-Symbor,
ADMINISTRATIONIS ASSOCIATED
Klaudia Sztolsztener, Karolina
WITH IMPROVED N-6/N-3 PUFA RATIO
Konstantynowicz-Nowicka
IN THE RED SKELETAL MUSCLE IN
and Adrian Chabowski
A RAT MODEL OF HIGH FATDIET-INDUCED OBESITY

P3 - 4Mor Cohen Harel*, Dikla Vardi
and David Meiri

GLIOBLASTOMA MULTIFORMETREATMENT BY COMBINATION OF
PHYTOCANNABINOIDS AND COMMONBRAIN CANCER DRUGS

P3 - 5

Fabian Kreilaus, Magdalena
Przybyla, Lars Ittner, Tim Karland Madilyn Coles*

CANNABIDIOL (CBD) TREATMENT
IMPROVES SPATIAL MEMORY
IN 14-MONTH-OLD FEMALE TAU58/2
TRANSGENIC MICE

P3 - 6

Madilyn Coles*, Georgia Watt,
Fabian Kreilaus and Tim Karl

MEDIUM DOSE CHRONICCANNABIDIOL TREATMENTREVERSES OBJECT RECOGNITIONMEMORY DEFICITS OF APPSWE/PS1ΔE9TRANSGENIC FEMALE MICE

P3 – 7

Luke Davison*and Jack Prenderville

ESTABLISHMENT OF A HUMAN
WHOLE BLOOD NLRP3INFLAMMASOME ACTIVATIONASSAY FOR EVALUATING NOVELINHIBITORS: ASSESSMENT
OF CANNABIDIOL

P3 – 8

Yara Eid Mutlak*, Hila NovakKotzer, Dor Samet, Anat
Gelfand and David Meiri

OPPOSING EFFECTS OF CANNABISEXTRACTS ON CD4 T REGULATORYCELLS DIFFERENTIATION
AND FUNCTION

P3 – 9Joerg Thilo Fischer*,
Javier Fernández-Ruiz,
Brahim Gargouri, Eduardo
Munoz, Matthias Winkler
and Bernd L. Fiebich

COMPARISON OF SYNTHETIC AND
PLANT-ISOLATED (-)-CANNABIDIOL ON
BINDING PROFILE AND ACTIVITY AT
CANNABINOID RECEPTORS

P3 – 10Anat Gelfand*, Gil M Lewitus,
Elazar Besser and David Meiri

CANNABINOIDS ATTENUATETHE SEVERITY OF COLITIS IN A
MURINE MODEL AND MODULATECXCR4 EXPRESSION

P3 – 11

Jonathan Gorelick*,
Tal Assa-Glazer, Noa Sela,
Abraham Nyska,
Nirit Bernstein
and Zecharia Madar

CANNABINOIDS AND CANNABISEXTRACTS AFFECT METABOLICSYNDROME PARAMETERSINCLUDING MICROBIOME IN MICEFED HIGH FAT-CHOLESTEROL DIET

P3 – 12

Mona Heiland*, Ngoc Thanh
Nguyen, Gary Brennan,
Thomas Hill, Gareth Morrisand David Henshall

EFFECTS OF PHYTOCANNABINOIDSON MICRORNA EXPRESSION IN TWOMODELS OF GENERALISED EPILEPSY

P3 – 13

Ewa Harasim-Symbor*,
Patrycja Bielawiec and Karolina
Konstantynowicz-Nowicka

CANNABIDIOL REGULATESMYOCARDIAL LIPID METABOLISM IN
A RAT MODEL OF OBESITY

P3 – 14

Erin Johnson*,
Shanna Babalonis
and Michael Kilgore

PHYTOCANNABINOID
CONCENTRATIONS IN HEMP DERIVED
PRODUCTS: LC-MS/MS ASSAY
VALIDATION AND QUANTIFICATIONOUTCOMES

P3 – 15

PHYTOCANNABINOIDS FOR
TREATING NON-ALCOHOLIC FATTYLIVER DISEASE, DYSLIPIDEMIA,
AND TYPE 2 DIABETES

P3 – 16

Magdalena Kostrzewa*, Ali
Mokhtar Mahmoud, Marianna
Cerasuolo, Roberto Ronca,
Sébastien Lacroix, Cristoforo
Silvestri, Vincenzo Di Marzoand Alessia Ligresti

EFFECT OF PHYTOCANNABINOIDS ON
ANDROGEN DEPRIVATION THERAPYIN A HIGH-FAT DIET EXACERBATEDPROSTATE CANCER

P3 – 17

Hunter Land, Marton Toth,
Laura MacNair, Siva Vanapalli,
Marcel Bonn-Miller, Erica
Peters and Tim Lefever*

TOXICITY AND LIFESPAN EFFECTS
OF CANNBIGEROL IN A PRECLINICAL
C. ELEGANS MODEL

P3 – 18

Radka Kočvarová*,
Shahar Azar and Joseph Tam

ABSTRACT WITHDRAWN

P3 – 19

Carni Lipson Feder*,Anna Shapira, Ohad Guberman,
Oded Cohen, Moshe Flaishman
and David Meiri

THE EFFECT OF CANNABIS FLOWERFERTILIZATION ON THE
ACCUMULATION OF SECONDARYMETABOLITES

P3 – 20

Yossef Ma’atuf*and Avi Priel

UNDERSTATING THE MOLECULARMECHANISM(S) OF CBD ANALGESICPROPERTIES

P3 – 21

Ali Mokhtar Mahmoud*,Viviana Marolda, Magdalena
Kostrzewa, Vincenzo Di Marzo,
Roberto Ronca
and Alessia Ligresti

CBD SELECTIVELY TARGETS THE
METABOLIC REPROGRAMMING OFHORMONE REFRACTORY PROSTATECANCER CELLS

P3 – 22

Nagina Mangal*, Patrick
Lawrence, Chanthirika
Ragulan, Krisha Desai, Barbara
Pacchetti, Vikash Reebye,
Mikael Sodergren
and Anguraj Sadanandam

THERAPEUTIC EFFECTS OFCANNABIDIOL IN COMBINATIONWITH CHEMOTHERAPY IN
PANCREATIC DUCTALADENOCARCINOMA

P3 – 23

Anna Paula Marçal*,Nícia Soares, Laila Asthand Daniele Aguiar

SUBCHRONIC TREATMENT
WITH CANNABIDIOL REVERSEDCOMPULSIVE-LIKE AND
ANXIOGENIC-LIKE EFFECTPROMOTED BY THE
CONSUMPTION OF HIGH-REFINEDCARBOHYDRATE DIET

P3 – 24

Elazar Besser, Gil Moshe
Lewitus, Hila Novak-Kotzer,
Shiri Procaccia, Paula Berman,
Inbar Shreiber-Livne, Yishai
Ofran and David Meiri*

ANTITUMOR EFFECT OF THREECANNABINOIDS ON LEUKEMIA
THROUGH INHIBITION OF NOTCH1PATHWAY

P3 – 25

Christina Miyabe Shields

TRANSFORMATION OF
PHYTOCANNABINOIDS BY HEAT –ISOMERIZATION, DEHYDRATION,
AND DERIVATIZATION OF
CANNABINOIDS PRESENT INCANNABIS SATIVA SMOKE

P3 – 26

Jakub Mlost*and Katarzyna Starowicz

NETWORK-BASED ANALYSIS OF
THERAPEUTIC TARGETS FORCANNABIDIOL IN NEUROPATHICCOMPONENT OF OSTEOARTHRITIS

P3 – 27

Mohammed Mustafa*,
Joel Schlosburg
and Aron H. Lichtman

CANNABIDIOL AS A DISCRIMINATIVESTIMULUS: AN EXPLORATORYINVESTIGATION

P3 – 28

Hila Novak-Kotzer*, Ronen
Rosenblum, Yara Eid Mutlak
and David Meiri

DISTINCT CANNABINOIDS
ALTER HUMAN TH17 CELLSDIFFERENTIATION AND FUNCTION

P3 – 29

Ryan Maguire,
Timothy Englandand Saoirse O'Sullivan*

THE EFFECTS OF CBD AND TMP
COADMINISTRATION IN CANCER

P3 – 30

Saba Omer*, Satyanarayana
Pondugula, Muralikrishnan
Dhanasekaran,
Mansour Mahmoud,Brad Matz and Dawn Boothe

IN VITRO CYTOTOXICITY OF
CANNABINOIDS IN COMBINATIONWITH COMPONENTS OF CHOPREGIMEN AGAINSTNON-HODGKIN LYMPHOMA

P3 – 31

Hadar Peeri*, Nurit Shalev,
Vinayaka Ajjampura, Dvora
Namdar, Anil Seegehalli,
Eduard Belausov Belausov
and Hinanit Koltai

CANNABIGEROL AND∆ -TETRAHYDROCANNABINOL FROMCANNABIS SATIVA INTERACT WITH
ADDITIONAL PHYTOCANNABINOIDSFOR CYTOTOXIC AND CELLMIGRATION INHIBITORY ACTIVITYON HUMAN GLIOBLASTOMA CELL
LINES IN-VITRO

P3 – 32

Paula Adriana Pitashny*,Ram Harari, Yoni Bar On
and Karen Jackson

CLASSIFICATION OF MEDICALCANNABIS STRAINS FOR TREATMENT
OF PAIN AND CONVULTIONS BYZEBRAFISH MODEL

P3 – 33

Prutchi Sagiv Sari*
and Maor Yehoshua

COMBINED ISOLATED CANNABINOIDSAS A POTENTIAL TOOL FOR WOMEN’SHEALTH INDICATIONS

P3 – 34

Rizelle Mae C. Rose*,
Maria Rivera-Garcia
and Adrianne R. Wilson-Poe

BEHAVIORAL AND HISTOLOGICALEFFECTS OF VAPORIZED FULLSPECTRUM CBD EXTRACT

P3 – 35

Daniela Schwotzer*,
Tim Lefever, Jake McDonald,
Kristen Trexler, Marcel BonnMiller and Mark Ware

PHYTOL, NOT PROPYLENE GLYCOL,CAUSES SEVERE PULMONARY INJURY
AFTER INHALATION DOSING IN
SPRAGUE-DAWLEY RATS

P3 – 36

Lior Spektor*, Liat RahamimBen Navi, Meshi Sadot
and David Meiri

THE ANTI-TUMOR EFFECTS
OF CANNABIS EXTRACTS ON
FAP SYNDROME AND
COLORECTAL CANCER

P3 – 37

Mark A. Tripson*, Katherine N.
Johnson and Ken Soderstrom

CANNABIDIOL EFFICACY TO
IMPROVE VOCAL RECOVERYIS ASSOCIATED WITH ANTIINFLAMMATORY AND
ANTIOXIDANT ACTIVITY

P3 – 38

Kiesha Wilson*,
Muthanna Sultan, Alkeiver
Cannon, Prakash S. Nagarkatti
and Mitzi Nagarkatti

TREATMENT OF SEB-INDUCED ARDS
WITH CBD AMELIORATES FATALINFLAMMATORY RESPONSE

P3 – 39

9

Iris Wyrobnik*, Hila NovakKotzer and Dedi Meiri

THE EFFECT OF CANNABIS ON
MYELOID-DERIVED SUPPRESSORCELLS IN MURINE MELANOMA

P3 – 40

H. Cannabinoid Drug Development & Delivery

Adam Ametovski*,Simon Cromwell, Hayley
Wilson, Charlotte Fletcher,
Samuel Banister, David Finlay,
Michelle Glassand David Lupton

Samuel Banister*, Eric Sparkes,
Adam Ametovski, Richard
Kevin, Elizabeth Cairns,
Katharina Grafinger, Annelies
Cannaert, Iain McGregor,
Michelle Glass, Mark Connor,
Volker Auwärter, Christophe
Stove and Roy Gerona

ENANTIOSELECTIVE SYNTHESISOF (−)-Δ9-THC AND NOVEL
C8-SUBSTITUTED (−)-NORMETHYL-Δ9THC ANALOGUESPHARMACOLOGICAL EVALUATIONOF RECENT SYNTHETICCANNABINOID RECEPTOR AGONISTS

P3 – 41

P3 – 42

Tamás Bíró*, Dalia Shabashov
Stone, Ilan Winkler
and Gary Hiller

FLUORINATED CANNABIDIOLDERIVATIVE PECS-101 EXERTSSUPERIOR ORAL BIOAVAILABILITYOVER CANNABIDIOL

P3 – 43

Cristiana Dumbraveanu*, Kai
Kummer, Katharina Strommer,
Astrid Neumann
and Michaela Kress

PHARMACOKINETIC PROFILE OF
BIOACTIVE SUBSTANCES THC AND
CBD AFTER ORAL CANNABISEXTRACTS ADMINISTRATION

P3 – 44

Shayma El-Atawneh*and Amiram Goldblum

MULTITARGETING THE
CANNABINOID RECEPTORS

P3 – 45

Laura Figuerola-Asencio*,
Dow P. Hurst, Linda M.
Console-Bram, Pingwei Zhao,
Nadine Jagerovic, Patricia H.
Reggio, Mary E. Aboodand Paula Morales

DISCOVERY OF NOVELGPR55 MODULATORS USING
LIGAND-BASED DRUG
DESIGN STRATEGY

P3 – 46

Natalya M. Kogan*,
Maximilian Peters
and Raphael Mechoulam

CANNABINOID QUINONES –SAR AND MECHANISMOBSERVATIONS

P3 – 47

Justyna Kulpa*, Graham Eglit
and Dana Vaughn

PHARMACOKINETIC ANALYSIS
OF CANNABIDIOL AND MAJOR
METABOLITES FOLLOWING ORALADMINISTRATION OF HEMP-DERIVEDCANNABINOID CHEWS IN
HEALTHY DOGS

P3 – 48

Ana Lago-Fernandez*, Pingwei
Zhao, Noori Sotudeh, Luciana
M. Leo, Eugen Brailoiu,
Dow P. Hurst, Paula Morales,
Patricia H. Reggio, Mary E.
Abood and Nadine Jagerovic

NOVEL SYNTHETIC COMPOUNDSWITH A CANNABIDIOL-LIKE
SCAFFOLD AS GPR18 LIGANDS

P3 – 49

Yarden Lavi*, Natalya Kogan,
Aviva Breuer, Zhanna Yekhtin,
Ruth Gallily
and Raphael Mechoulam

A NOVEL ROUTE TO METHYL
SUBSTITUTIONS ON THE AROMATIC
RING OF CANNABINOIDS

P3 – 50

Evangelos Dadiotis, Aikaterini
Papakonstantinou, Vangelis
Mitsis, Haralabia Boleti,
Eleni Melliou
and Prokopios Magiatis*

SIMULTANEOUS EXTRACTION ANDSYNTHESIS OF NEW CANNABINOIDSACID ESTERS AND THEIR IN VITROCYTOTOXICITY ASSESSMENT IN
BREAST CANCER CELL LINES

P3 – 51

Jack Markham*, Eric Sparkes,
Jia Lin Lao, Richard Kevin,
Christa Macdonald, Rochelle
Boyd, Michelle Glass, Mark
Connor, Iain McGregor andSamuel Banister

DEFINING STERIC LIMITS IN A SERIESOF SYNTHETIC CANNABINOID
RECEPTOR AGONISTS RELATED TO
5F-AB-PICA, 5F-ADB-PICA AND PX-1

P3 – 52

Paula Morales*, Gemma
Navarro, Marc Gómez-Autet,
Laura Redondo, Javier
Fernández-Ruiz, Laura PérezBenito, Arnau Cordomí,
Leonardo Pardo, Rafael Franco
and Nadine Jagerovic

CHROMENOPYRAZOLE-BASED
CB2 BITOPIC LIGANDS

P3 – 53

Amal M. Shoeib*,
Lance N. Benson, Shengyu Mu
and Paul L. Prather

CANNABINOID RECEPTORSEXPRESSED IN PROSTATE AND
OTHER CANCER CELL LINES EXHIBITATYPICAL BINDING AND SIGNALINGPROPERTIES: IMPLICATIONS FORDRUG DEVELOPMENT

P3 – 54

Eric Sparkes*, Monica Patel,
Katharina Elisabeth Grafinger,
Elizabeth Cairns, Ross Ellison,
Iain Stuart McGregor, Roy
Roberto Gerona, Volker
Auwärter, Michelle Glass andSamuel Douglas Banister

CHEMISTRY AND PHARMACOLOGYOF SYNTHETIC CANNABINOID
RECEPTOR AGONISTS ADB-BINACA
APP-BINACA ADB-P7AICA AND THEIRANALOGUESP3 – 55

Kim Sugamori*, Catharine
Mielnik, David Finlay,
Mohammed Mustafa, Daniel
Liput, Vincent Lam, Mostafa
Abdelrahman, Laurent
Trembleau, Ali Salahpour,
Amy Ramsey, David Lovinger,
Aron Lichtman, Michelle Glass,
Iain Greig and Ruth Ross

NOT ALL ALLOSTERIC MOLECULESARE CREATED EQUAL: EVIDENCEFOR SELECTIVE EFFECTIVENESS IN
DOPAMINE-DYSREGULATEDSYMPTOMS BY CB1 ALLOSTERICMODULATORS

P3 – 56

Almog Uziel*, Anat Gelfand,
Keren Amsalem, Paula Berman,
Gil Lewitus, David Meiri
and Dan Lewitus

SUSTAINED-RELEASE OF WHOLE
PLANT MEDICAL CANNABIS VIAMELT-PRINTED POLYMERICMICRODEPOTS

P3 – 57

I. Cannabinoid Interactions with Drugs of Abuse

Lihi Bar-Lev Schleider*and Victor Novack

DECREASE IN OPIOIDSCONSUMPTION IN PATIENTSRECEIVING MEDICAL CANNABIS

P3 – 58

Rayssa Briânis*and Fabricio Moreira

EFFECTS OF CANNABIDIOL ON
REWARDING AND AVERSIVECONTEXTUAL MEMORIES INDUCEDBY COCAINE AND LITHIUM

P3 – 59* Presenting author

POSTER SESSION 4 – Topics J-L
DAY 4, Thursday, June 24th

J. Cannabis Human Studies - Part 2
Maria-Fernanda Arboleda*,
Lucile Rapin, Cynthia El Hage,
Michael Dworkind
and Erin Prosk

CANNABINOID-BASED MEDICINESFOR CHRONIC PAIN:
FACTORS THAT IMPACT
TREATMENT EFFECTIVENESS

P4 – 1

Alex Bibikau*
and Aleks Petrova

COMPREHENSIVE ANALYSIS OF THE
IMPACT OF MEDICAL CANNABISTREATMENT ON PTSD SYMPTOMS,ANXIETY AND DEPRESSION LEVELS,TOBACCO SMOKING, ALCOHOLABUSE, THE USE OF PSYCHOACTIVE
PHARMACEUTICALS,AND QUALITY OF LIFE

P4 – 2

Simon Erridge*, Oliver Salazar,
Michal Kawka, Carl Holvey,
Ross Coomber, Azfer Usmani,
Mohammed Sajad, Sushil Beri,
Jonathan Hoare, Shaheen Khan,
Mark Weatherall, Michael Platt,James Rucker
and Mikael Sodergren

AN INITIAL ANALYSIS OF THE UK
MEDICAL CANNABIS REGISTRY

P4 – 3Olivia First*, Kimber
MacGibbon, Catherine Cahill,
Ziva Cooper, Lilian Gelberg,
Victoria Cortessis, Patrick
Mullin and Marlena Fejzo

TRENDS IN CANNABIS USE FOR
HYPEREMESIS GRAVIDARUM

P4 – 4Ari Greis*, Eric Larsen,
Conan Liu, Bryan Renslo,
Anjithaa Radakrishnan
and Adrianne R. Wilson-Poe

THERAPEUTIC EFFICACY,
REDUCED PRESCRIPTION DRUG USE,
AND MINIMAL SIDE EFFECTS OFCANNABIS IN PATIENTS WITH
CHRONIC ORTHOPEDIC PAIN

P4 – 5Maja Kalaba*, Wendy Mak,
Alistair Vickery,
Tracie Ernenwein, Patrizia
Washer, Graham Eglit
and Matthew Feldner

REAL-WORLD EVIDENCEDESCRIBING AUSTRALIANMEDICINAL CANNABIS PATIENTS,
SAFETY, AND TREATMENTOUTCOMES

P4 – 6Maja Kalaba*, Erica Peters,
Chanez N. Kebacheand Mark A. WareSEX DIFFERENCES AMONG ADVERSEEVENTS TO CANNABIS

P4 – 7

Robert Kaufmann*and Vince Sanders

NANO-PROCESSED CBG/CBD: EFFECT
ON PAIN, ATTENTION DEFICIT
AND HYPERACTIVITY DISORDER,
IRRITABLE BOWEL SYNDROME,
AND CHRONIC FATIGUE

P4 – 8Robert Kaufmann*and Vince Sanders

USE OF A WATER-SOLUBLE FORM OFCANNABINOL FOR THE TREATMENTOF SLEEPLESSNESSP4 – 9Stephanie Lake*, Ryan Assaf,
Pamina Gorbachand Ziva Cooper

CANNABIS USE FOR ANXIETY DURING
THE COVID-19 PANDEMIC IN THE
UNITED STATES

P4 – 10

Rachael Rzasa Lynn, Gregory
Kinney, Rahwa Netsanet,
Vikas Patel, Michael Finn
and Emily Lindley*

USE OF CANNABIS TO SELFMEDICATE FOR CHRONIC SPINE PAIN

P4 – 11

Laura Macnair*, Erica Peters,
Graham Eglit, Irina Mosesova,
Ryan Vandrey, Hunter Land,
Mark Ware, Cynthia Turcotteand Marcel Bonn-Miller

SEX DIFFERENCES IN SAFETY,PHARMACOKINETICS, AND
PHARMACODYNAMICS OF TWO ORALMEDICAL CANNABIS PRODUCTS
AMONG HEALTHY ADULTS

P4 – 12Danielle McCartney*,Anastasia S. Suraev, Richard C.
Kevin, Christopher Irwin,
Melissa J. Benson, Ronald R.
Grunstein, Camilla M. Hoyos
and Iain S. McGregor

EFFECTS OF CANNABIDIOL (CBD) ON
SIMULATED DRIVING AND
COGNITIVE PERFORMANCE: A
RANDOMISED CONTROLLED TRIAL

P4 – 13

Kenneth Blum, Joseph
Morgan*, Jean Lud Cadet,David Baron, Paul Carney,
Jag Khalsa and Mark Gold

MORE CANNABIS-INDUCEDHYPODOPAMINERGIC ANHEDONIA
AND COGNITIVE DECLINE FROMLEGALIZATION REQUIRING
PUTATIVE INDUCTION OF DOPAMINEHOMEOSTASIS AND POTENTIALOPIOID RESTORATION MODELING?

P4 – 14

J. Patrick Neary*,
Jyotpal Singh,
Taylor A. Teckchandaniand Lanishen Bhagaloo

EFFECT OF FULL SPECTRUM
CANNABIDIOL ON HEART RATEVARIABILITY AND PSYCHOLOGICALSTRESSORS IN MILD TRAUMATIC
BRAIN INJURY: CASE SERIES

P4 – 15Natalia Parraguez*, Cynthia
Lebron, Scylla Blervacq
and Denise Vidot

WORRY AMONG PREGNANT AND
BREASTFEEDING WOMEN CANNABISCONSUMERS IN THE UNITED STATESDURING THE COVID-19 PANDEMIC

P4 – 16

Erica Peters*, Irina Mosesova,
Laura MacNair, Ryan Vandrey,
Hunter Land, Mark Ware,
Cynthia Turcotteand Marcel Bonn-Miller

SAFETY, PHARMACOKINETICS,
AND PHARMACODYNAMICSOF SPECTRUM RED SOFTGELSIN HEALTHY PARTICIPANTS

P4 – 17

Erica Peters*, Laura MacNair,
Irina Mosesova, Uwe
Christians, Cristina Sempio,
Jost Klawitter, Hunter Land,
Mark Ware, Cynthia Turcotteand Marcel Bonn-Miller

CANNABICHROMENE:
PHARMACOKINETICS IN HEALTHY
ADULT PARTICIPANTS

P4 – 18

Hudson Reddon*, Cameron
Grant, Ekaterina Nosova, Kora
DeBeck and M-J Milloy

CANNABIS USE AND THE INCIDENCE
OF MENTAL HEALTH DIAGNOSES: A
12-YEAR STUDY OF PEOPLE WHO USEDRUGS IN A CANADIAN SETTING

P4 – 19

Dror Robinson

LONG-TERM FOLLOW-UP OF
MEDICAL CANNABIS THERAPY IN
LOW BACK PAIN RESULT OF A
SEQUENTIAL 500-PATIENT COHORT

P4 – 20

Addie Ron*, Vered Hermush
and Lihi Bar-Lev Schleider

THE EFFECT OF MEDICAL CANNABISTREATMENT ON POLYPHARMACYIN OLDER ADULTS

P4 – 21

Yakir Rottenberg

RISKS FACTORS FOR POTENTIAL
ADDICTION AMONG CANCERPATIENTS WHO USE
MEDICAL MARIJUANAP4 – 22

Ashley Schnakenberg Martin*,Jose Cortes-Briones, Patrick
Skosnik, Leigh Flynn, Esra
Sefik, Christina Luddy,
Mohini Ranganathan
and Deepak D'SouzaETHANOL AND THC EFFECTS
ON SIMULATED DRIVING

P4 – 23

Gregory L. Smith

HAIR REGROWTH WITH TOPICALLYAPPLIED CANNABIDIOL (CBD) IN
HEMP EXTRACT - A CASE SERIES

P4 – 24

Sharon Sznitman*, Dennis
Rosenberg, Simon Vulfsons,David Meiri and Talya Greene

MEDICAL CANNABIS USE AND PAIN:
AN EXPERIENCE SAMPLING STUDY

P4 – 25

Eef Theunissen*, Johannes
Reckweg, Nadia Hutten,
Kim Kuypers
and Johannes Ramaekers

ACUTE INTOXICATION BY A
SYNTHETIC CANNABINOID (JWH-018):
COGNITIVE, PSYCHOMOTOR AND
PSYCHOTOMIMETIC EFFECTS

P4 – 26

Marisa Weiss*, Katherine Ruiz,
Meghan Buckley, Meske Sam,Kjelstrom Stephanie, Danese
Sherry, Adam Leitenberger,
Melissa Bollmann-Jenkins,
Julianne Hibbs, Sharon Larson,
Nancye Greenand Diana Martinez

CANNABIS PRODUCTPREFERENCES IN U.S.-BASEDBREAST CANCER PATIENTS

P4 – 27

Marisa Weiss*, Meghan
Buckley, Katherine AlianoRuiz, Stephanie Kjelstrom, Sam
Meske, Sherry Danese, Adam
Leitenberger, Melissa Bollmann
Jenkins, Julianne Hibbs, Sharon
Larson, Nancye Green, Paul
Gilman and Diana Martinez

A SURVEY: ATTITUDES TOWARDSCANNABIS USE IN PEOPLE WITH
BREAST CANCER

P4 – 28

Dylan Zylla*, Grace Gilmore,
Justin Eklund, Jordan
Guggisberg and Sara Richter

A SURVEY OF PATIENTS WITHCANCER WHO REPORT ANTI-CANCER
BENEFITS OF CANNABIS USE

P4 – 29

K. Novel CB1 Modulators

George Amato*, Ann Decker,
Danni Harris, Scott Runyon
and Rangan Maitra

SAR EFFORTS TOWARDSPERIPHERALIZATION OF THE
CANNABINOID RECEPTOR PARTIALAGONIST BAY 59-3074

P4 – 30

Beth Wiese*, Erika LiktorBusa, Sarah Couture, Spyros
Nikas, Lipin Ji, Yingpeng Liu,
Alexandros Makriyannis, Igor
Spigelman, Todd Vanderah
and Tally Largent-Milnes

BRAIN PENETRANT, BUT NOTPERIPHERALLY RESTRICTED,SYNTHETIC CANNABINOID 1
RECEPTOR AGONISTS PROMOTEMORPHINE-MEDIATEDRESPIRATORY DEPRESSION

P4 – 31

L. THC

Samantha Baglot*, Catherine
Hume, Robert Aukema, Gavin
Petrie, John Bieber, Ryan
McLaughlin and Matthew Hill

INHALED CANNABIS DELIVERY
DURING PREGNANCY: MATERNALFETAL TRANSMISSION AND EFFECTSON FETAL AMYGDALADEVELOPMENT

P4 – 32

Christian Cabanlong*,
Paul Prather
and Lee Ann MacMillan-Crow

SYNTHETIC CANNABINOIDS AND 9DTHC DIFFERENTIALLY MODULATE
MITOCHONDRIAL FUNCTION IN
NORMAL RAT KIDNEY (NRK) CELLS

P4 – 33

Danilo De Gregorio*, Joshua
Dean Conway, Martha LopezCanul, Luca Posa, Francis
Rodriguez Bambico
and Gabriella Gobbi

EFFECTS OF CHRONICEXPOSURE TO LOW DOSE OF
D9- TETRAHYDROCANNABINOL IN
ADOLESCENCE AND ADULTHOOD ON
SEROTONIN/NOREPINEPHRINENEUROTRANSMISSION AND
EMOTIONAL BEHAVIORS

P4 – 34

Megan Drupals*, Janice Hicks,
Shoshana Spring, Tina Weng,
Ben Darwin, Lindsay Cahill,
Brian Nieman, John Sled,
Ameet Sengar, Benjamin
Steinberg and Michael Salter

EFFECTS OF PRENATAL NABILONEEXPOSURE ON MOUSE GESTATIONAND EMBRYO MORPHOLOGYUSING MICRO-CT IMAGING

P4 – 35

Lorena Galera-López*, Victòria
Salgado-Mendialdúa, Irene
Manzanares, Araceli BergadàMartínez, Estefanía Moreno,
Vicent Casadó, Alexander
Hoffman, Carl Lupica, Rafael
Maldonado and Andrés Ozaita

REPEATED LOW DOSES OF
Δ9-TETRAHYDROCANNABINOL
AFFECTS MEMORY PERFORMANCE
THROUGH SEROTONERGIC
SIGNALING IN MICE

P4 – 36

Briana Hempel*, Guo-Hua Bi,
Madeline Crissman, Sruti Pariand Zheng-Xiong Xi

AN INVESTIGATION OF PPARΑ AND
PPARΓ IN THE CNS EFFECTS OF
Δ9-THC IN MICE

P4 – 37

Catherine Hume*, Samantha
Baglot and Matthew Hill

CHARACTERISING‘THE MUNCHIES’; EFFECTS OFTETRAHYDROCANNABINOL (THC)
VAPOUR EXPOSURE ON RATFEEDING BEHAVIOURS

P4 – 38

Joanna Agnieszka
Komorowska-Müller*, AnneKathrin Gellner, Kishore
Aravind Ravichandran, Andreas
Zimmer and Valentin Stein

LOW-DOSAGE THC TREATMENTDIFFERENTLY ALTERS SPINEDYNAMICS IN OLD AND YOUNG MICE

P4 – 39

Savannah Lightfoot*, Samantha
Baglot, Catherine Hume, Ryan
McLaughlin and Matthew Hill

INVESTIGATING STRESS REACTIVITY
IN RATS FOLLOWING ACUTE THC
VAPOUR EXPOSURE

P4 – 40

Allen Mello*, Denise Valenti
and Sabra Botch-Jones

DETECTION OF Δ9TETRAHYDROCANNABINOL AND
METABOLITES IN THE MEIBOMIAN
LIPIDS OF TEAR SAMPLES THROUGH
LC-MS/MSP4 – 41

Iu Raïch, Rafael RivasSantisteban, Catalina PérezOlives, Eddy Sotelo, María
Teresa García-Valverde, Carlos
Ferreiro-Vera, Gemma
Navarro*, Xavier Nadal-Roura,
Verónica Sánchez de Medina
and Rafael Franc

PHARMACOLOGICAL
CHARACTERIZATION AND BIASEDSIGNALING OF THC, THCA AND THCVIN CANNABINOID CB1 AND CB2
RECEPTORS

P4 – 42

Todd M. Stollenwerk*
and Cecilia J. Hillard

SEX-DEPENDENT EFFECTS OFADOLESCENT THC EXPOSURE ON
COGNITIVE PERFORMANCE IN A
MOUSE MATERNAL IMMUNEACTIVATION MODEL OF
SCHIZOPHRENIA

P4 – 43

Hayley H. A. Thorpe*, M.
Asfandyaar Talhat, Sandra
Sanchez-Roige, Abraham A.
Palmer, and Jibran Y. Khokhar

EFFECTS OF CADM2 VARIATION ON
PREFERENCE FOR AND
CONSUMPTION OF THC- AND
CANNABIS OIL-INFUSEDCOOKIE DOUGH

P4 – 44

Alexa Torrens*, Valentina
Vozella, Cindy Vu, Dakota
Grimes, Faizy Ahmedand Daniele Piomelli

COMPARATIVE PHARMACOKINETICSOF D9-TETRAHYDROCANNABINOL IN
ADOLESCENT AND ADULT MICEAND RATSP4 – 45* Presenting author

LATE-BREAKING RESEARCH
Mehmet Ergisi*, Simon
Erridge, Michael Harris, Michal
Kawka, Devaki Nimalan, Oliver
Salazar, Katerina Loupasaki,
Rayyan Ali, Carl Holvey, Ross
Coomber, Azfer Usmani,
Mohammed Sajad, Sushil Beri,
Jonathan Hoare, Shaheen Khan,
Mark Weatherall, Michael Platt,James Rucker
and Mikael Sodergren

AN UPDATED ANALYSIS OF GENERAL
CLINICAL OUTCOME MEASURESACROSS PATIENT GROUPS IN THE UK
MEDICAL CANNABIS REGISTRY

LB – 1

Mehmet Ergisi*, Simon
Erridge, Michael Harris, Michal
UK MEDICAL CANNABIS REGISTRY:
Kawka, Devaki Nimalan, Oliver
AN ANALYSIS OF CLINICALSalazar, Katerina Loupasaki,
OUTCOMES OF MEDICINAL CANNABIS
Rayyan Ali, Carl Holvey, Ross
THERAPY FOR ANXIETY
Coomber, Michael Platt, James
Rucker and Mikael Sodergren

LB – 2

Simon Erridge*, Ross Coomber
and Mikael Hans Sodergren

MEDICAL CANNABIS, OVER-THECOUNTER CBD AND PUBLIC OPINION
IN THE UNITED KINGDOMLB – 3

Christa Frodella*and Barbara Kaplan

PILOT STUDY REVEALS SEXDIFFERENCES IN T CELL
STIMULATED MOUSE SPLENOCYTES
PRE-TREATED WITH CANNABIDIOLLB – 4

Michael Harris*, Simon Erridge,
Mehmet Ergisi, Devaki Nimalan,
Michal Kawka, Oliver Salazar,
Rayyan Ali, Katerina Loupasaki,
Carl Holvey, Ross Coomber,
Azfer Usmani, Mohammed Sajad,
James Rucker, Michael Plattand Mikael Sodergren

EXPLORING QUALITY OF LIFEOUTCOMES OF CHRONIC PAIN
PATIENTS FROM THE UK MEDICALCANNABIS REGISTRY

LB – 5Karolina KonstantynowiczNowicka*, Klaudia Sztolsztenerand Ewa Harasim-Symbor

THE INFLUENCE OF CANNABIDIOL ON
FATTY ACID TRANSPORTERS AND
LIPID ACCUMULATION DURINGNONALCOHOLIC FATTY LIVERDISEASE DEVELOPMENT

LB – 6

Sean Madden*, Cameron
Haslip, Monica Tomlinson
and Nehal Vadhan

THE IMPACT OF THE CORONAVIRUS
PANDEMIC ON CANNABIS USE
PATTERNS IN THE NEW YORKMETROPOLITAN AREA:A LONGITUDINAL SURVEY

LB – 7

Nagina Mangal*, Vikash
Reebye, Barbara Pacchetti,
Anguraj Sadanandam
and Mikael Sodergren

CERAMIDE SYNTHASE ISOFORMS
ARE UPREGULATED BY CANNABIDIOLRESULTING IN CYTOTOXICEFFECTS IN PANCREATICDUCTAL ADENOCARCINOMA

LB – 8

Devaki Nimalan*, Michal
Kawka, Simon Erridge,
Mehmet Ergisi, Michael Harris,
Oliver Salazar, Rayyan Ali,
Katerina Loupasaki, Carl
Holvey, Ross Coomber,Michael Platt, James Rucker,
Shaheen Khan and Mikael
Sodergren

ANALYSIS OF PALLIATIVE CARE
PATIENTS FROM THE UK MEDICALCANNABIS REGISTRY: INITIAL
EXPERIENCE AND OUTCOMES

LB – 9Marzia Pendino*, Sandra
Garcia Mulero, Rebecca Sanz
Pamplona, Simone Marcone,
Kayleigh Slater, Josep Piulats
and Breandan Kennedy

EVALUATING THE CB1 RECEPTOR
AS A THERAPEUTIC TARGETFOR UVEAL MELANOMALB – 10

Ayshe Sahinovic*, Christopher
Irwin, Peter Doohan, Richard
Kevin, Amanda Cox, Namson
Lau, Ben Desbrow, Nathan
Johnson, Angelo Sabag,
Matthew Hislop, Paul Haber,
Iain McGregor
and Danielle McCartney

THE EFFECT OF CANNABIDIOL(CBD) ON EXERCISE PHYSIOLOGYAND BIOENERGETICS:
A RANDOMISED CONTROLLEDPILOT TRIAL

LB – 11

Lucía Vignale*, Lucía Malta
and Astrid Agorio

CANNABINOID SYNTHASES GENE
COPY NUMBER AND EXPRESSIONANALYSIS IN CANNABIS VARIETIESFOUND IN URUGUAY

LB – 12

Taryn Bosquez*, Sierra Wilson,
Christos IliopoulosTsoutsouvas, Shan Jiang,
Spyros Nikas, Alexandros
Makriyannis, Ken Mackie
and Alex Straiker

DIFFERENTIAL ENANTIOMERSPECIFIC SIGNALING OFCANNABIDIOL AT CB1 RECEPTORSLB – 13

2021 © International Cannabinoid Research Society